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10 | Chapter 1
1.1 Migraine
 1.1.1 Migraine epidemiology and socioeconomic impact
Migraine is a common neurovascular disease, with a lifetime prevalence of 33% 
for women and 13% for men. At least 12% of the Dutch population suffers from 
at least 1-2 attacks per month. (1) The personal and socioeconomic burden of 
migraine is enormous. A recent report of the Global Burden of Disease Study 
2015 listed migraine 8th out of 289 diseases for ‘global years lived with disability’. 
(2, 3) Migraine was the leading cause of disability among neurological disorders, 
accounting for over half of all years lived with disability. (4) In high-income 
countries, the total disability due to migraine is more than 1.5 times that due to 
multiple sclerosis and Parkinson’s disease combined, and almost 3 times that due 
to epilepsy. (2) The economic burden caused by migraine is the second highest of 
all brain diseases, with an estimated annual cost of €111 billion in the European 
Union alone. (5) 
 1.1.2 Migraine criteria and characteristics of the migraine attack
Diagnoses are based on criteria that have been provided by the International 
Headache Society in 1988 (ICHD-I), being revised in 2004 (ICHD-II) and 2013 
(ICHD-III beta). (6-8) Following these criteria, migraine is characterized by recurrent, 
disabling attacks of severe, unilateral, throbbing headache that aggravates by 
physical activity. (8) If untreated, attacks last 4-72 hours. The headache is typically 
accompanied by nausea or vomiting, photophobia and phonophobia, or a 
combination of these additional symptoms. In up to 30% of migraineurs, attacks 
may be associated with reversible focal neurological aura symptoms, mostly 
visual, such as scotomas and scintillations, and sometimes sensory symptoms 
or dysphasia (migraine with aura). The typical duration of migraine auras is 5-60 
minutes. The aura gradually expands, and the aura phase typically precedes the 
headache phase, although some patients describe an overlap, or a short gap 
between the end of the aura phase and the onset of headache. (9, 10)  A few 
hours up to 2 days prior to the aura and headache phase, migraine patients may 
experience a wide variety of non-headache premonitory symptoms. Reported 
symptoms are fatigue, weariness, yawning, stiff neck, gastrointestinal problems, 
mood and cognitive changes, temperature change, smell and taste distortion, 
increased perceived stress and food craving. (11-14). The recovery phase, which 
can last up to a few days, is characterized by symptoms that are quite similar to 
premonitory symptoms: tiredness, weakness, cognitive difficulties, mood changes, 
residual headache, light-headedness and gastrointestinal problems. (15, 16) Table 
1 describes the full ICHD-III beta criteria for migraine with and without aura. 
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Table 1: Classification of migraine without aura and migraine with aura according to 
the ICHD-III beta criteria.
Migraine without aura
A. At least five attacks fulfilling criteria B-D
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following four characteristics:
   1. Unilateral location
   2. Pulsating quality
   3. Moderate or severe pain intensity
   4. Aggravation by or causing avoidance of routine physical activity 
                   (e.g. walking or climbing stairs)
D. During headache at least one of the following:
   1. Nausea and/or vomiting
   2. Photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis.
Migraine with typical aura
A. At least two attacks fulfilling criteria B and C 
B. Aura consisting of visual, sensory, and/or speech/language symptoms, each      
        fully reversible, but no motor, brainstem of retinal symptoms
C. At least two of the following four characteristics:
   1. At least one aura symptom spreads gradually over 5 minutes, and/or   
                    two or more symptoms occur in succession
   2. Each individual aura symptom lasts 5-60 minutes
   3. At least one aura symptom is unilateral
   4. The aura is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for by another ICHD-3 diagnosis, and transient 
        ischaemic attack has been excluded.
 Typical aura with headache
A. Fulfils criteria for Migraine with typical aura
B. Headache, with or without migraine characteristics, accompanies or follows the 
        aura within 60 minutes.
 Typical aura without headache
A. Fulfils criteria for Migraine with typical aura
B. No headache accompanies or follows the aura within 60 minutes
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 1.1.3 Migraine pathophysiology
Migraine is associated with activation of the trigeminovascular system. (17) 
Through this system, which connects brainstem nuclei with dural blood vessels 
via the ophthalmic division of the trigeminal nerve, abnormal pain signals are 
transferred from the dura to higher order central nervous systems during a migraine 
attack. Activation of trigeminovascular efferents leads to release of vasoactive 
neuropeptides (e.g. Calcitonin Gene Related Peptide (CGRP), Substance P), which 
are believed to be involved in neurogenic inflammation, central pain transmission, 
and headache. Sustained activation of the trigeminovascular system leads to 
peripheral sensitization of first-order trigeminal neurons, which thus exhibit 
increased responsiveness to external stimuli. Central sensitization is elicited by 
increased excitability of second and third order neurons (in the dorsal horn of 
the spinal cord and in the thalamus), a result of persistent pain transmission. As a 
result of central sensitization, non-noxious stimuli of the peri-orbital skin (which is 
also innervated by the ophthalmic division of the trigeminal nerve) are perceived 
as painful, a phenomenon known as cutaneous allodynia. This phenomenon 
occurs during attacks in 50-80% of all migraine patients. (18) It is well accepted 
that migraine aura is most likely caused by the human equivalent of the cortical 
spreading depression of Leao, a wave of depolarization that propagates slowly 
across the cortex. (19) 
 1.1.4 Migraine genetics
Migraine has a strong genetic component, as shown in population-based family 
studies and twin studies. (20) A number of loci were discovered over the past 
decade using the genome wide association (GWA) approach, pointing at genes 
that cluster in pathways for glutamatergic neurotransmission, synaptic function, 
pain sensing, metalloproteinases, and the vasculature. (21-25) The individual 
pathogenic contribution of each gene variant, however, is difficult to assess. 
Familial hemiplegic migraine (FHM) is a rare monogenic subtype of migraine with 
aura, with transient hemiparesis during the aura phase. Ever since the discovery of 
the three genes that have been associated with hemiplegic migraine (CACNA1A 
(FHM1), ATP1A2 (FHM2) and SCN1A (FHM3)) it has been considered a suitable 
model to gain more insight into the pathophysiology of common migraine. 
(26-28) All three FHM gene products are involved in the modulation of ion 
transport across neuronal and glial cell membranes, suggesting that FHM, and 
possibly also common types of migraine, at least in part, are cerebral ‘ionopathies’. 
  1
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 1.1.5 Migraine treatment
Acute treatment of migraine attacks follows a stepped-care principle. Medication 
of first choice is a simple analgesic, like paracetamol or an NSAID. When these 
appear insufficient, triptans should be prescribed. Triptans are agonists of the 5HT-
1B/1D-receptor, and were introduced in 1991 as a new treatment for migraine and 
cluster headache attacks, replacing the ergotamins. When migraine frequency 
exceeds 2 attacks per month or in case of insufficient response to attack medication, 
prophylactic medication may be started. Examples of migraine prophylaxis are 
valproate, propranolol, topiramate and candesartan. 
  1.1.6 Migraine chronification
Up to 25% of migraine patients will at one point during their lifetime meet the 
definition for chronic migraine. (29) According to the ICHD-III beta classification 
criteria, a clinical diagnosis of chronic migraine (the prevalence of which is 
estimated to be around 0.5 to 2.0% among the general population) is made when 
a migraine patient has 15 or more days with headache per month, of which at least 
eight days have features of migraine headache (or being relieved by migraine-
specific medication). (8, 30, 31) Table 2 describes the full criteria for chronic 
migraine. 
Table 2: Classification of chronic migraine according to the ICHD-III beta criteria.
Chronic migraine
A. Headache (tension-type-like and/or migraine-like) on ≥15 days per month for 
        >3 months and fulfilling criteria B and C
B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for   
       Migraine without aura and/or criteria B and C for Migraine with aura
C. On ≥8 days per month for > 3 months, fulfilling any of the following:
1. Criteria C and D for Migraine without aura
2. Criteria B and C for Migraine with aura
3. Believed by the patient to be migraine at onset and relieved by a 
       triptan or ergot derivative
D. Not better accounted for by another ICHD-3 diagnosis.
Chronification of migraine occurs about equally in male and female migraineurs. 
It is thought that in these patients the threshold for migraine attacks is lowered 
compared to episodic migraineurs, but the exact mechanism behind this 
chronically lowered threshold remains unknown. One of the main factors 
associated with chronic migraine is the overuse of acute migraine medication. (32) 
In European clinical practice, almost all chronic migraineurs also fulfil the criteria 
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for medication overuse headache, which is the consequence of regular overuse of 
acute anti-migraine medication. Table 3 describes the full criteria for medication 
overuse headache.
Table 3: Classification of medication overuse headache according to the ICHD-III beta 
criteria.
Medication overuse headache
A. Headache occurring on ≥15 days per month in a patient with a pre-existing 
        headache disorder
B. Regular overuse for >3 months of one or more drugs that can be taken for 
       acute and/or symptomatic treatment of headache
C. Not better accounted for by another ICHD-3 diagnosis.
Overuse is defined differently for triptans (on ≥10 days per month for >3 months) 
than for simple analgesics like paracetamol or NSAIDs (on ≥ 15 days per month for 
>3 months). ‘Combination-analgesic-overuse headache’ is defined as headache 
fulfilling the criteria for medication overuse headache, with a regular intake of 
one or more combination-analgesic medications on ≥10 days/month for > 3 
months. ‘Medication-overuse headache attributed to multiple drug classes not 
individually overused’ is defined as headache fulfilling the criteria for medication 
overuse headache, with regular intake of any combination of ergotamine, triptans, 
simple analgesics, NSAIDs and/or opioids on a total of ≥10 days per month for >3 
months, without overuse of any single drug or drug class alone.
Although consensus about the optimal treatment for both medication overuse 
headache and chronic migraine has not yet been reached, withdrawal of the 
overused medication is strongly suggested as an essential component in the 
management of these diseases. (33-35) In The Netherlands, treatment of chronic 
migraine and medication overuse headache consists of cold-turkey withdrawal 
of all analgesics, triptans, and caffeine, during 3 months (in case of involvement 
of simple analgesics) or 2 months (in case of isolated triptan overuse). After 
withdrawal, most patients show a clear decrease in the number of headache days 
per month, with a more recognizable pattern of migraine attacks and migraine-free 
periods. Symptomatic and/or prophylactic treatment may be started again after 
withdrawal, with a clear explanation to the patient about the risks of medication 
overuse.
Two randomised, double-blind, controlled trials (PREEMPT1 and PREEMPT2) 
showed an effect of Onabotulinum toxin A injections (without withdrawal of the 
overused acute headache medications) in the treatment of chronic migraine. 
(36-38) The pooled results of both trials show a small but significant advantage 
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of Onabotulinum toxin A injections above placebo (Onabotulim toxin A group: 
-8.4 headache days; placebo group: -6.6 headache days). This small difference, 
however, probably does not reach the standard for clinical relevance. Importantly, 
although there was a decrease in frequency of headache days (both in the verum 
and placebo groups), there was no decrease in the intake of acute headache pain 
medication. The risk of unblinding in the PREEMPT trials also remains a topic of 
discussion. 
1.2 Depression
 1.2.1 Depression epidemiology and socioeconomic impact
Depression, like migraine, is a chronic episodic brain disorder, with a lifetime 
prevalence of 19% and a 1-year prevalence of 6% in the Dutch population. (39) 
Major depressive disorder is among the most disabling psychiatric disorders in 
adult age and has the second largest global disease burden, after low back pain. 
(2)
 1.2.2 Depression criteria and characteristics of a depressive episode
Clinical diagnoses are based on diagnostic criteria that have been provided by 
the Diagnostic and Statistical Manual of Mental Disorders, DSM. The first version 
of this diagnostic classification was published in 1952, and the last version 
hitherto, DSM-5, has been published in 2013. (40) Depression is characterized 
by a persistent low or sad mood, anhedonia, difficulties in eating and sleeping, 
concentration problems, psychomotor agitation or retardation, tiredness, feelings 
of worthlessness or guilt, and thought about death or suicide. The symptoms 
must persist for most of the day, nearly every day, for at least 2 consecutive weeks. 
The course of a depressive episode is highly variable. Some individuals reach 
rapid remission (a period of 2 months without symptoms, or only one or two 
symptoms with a mild degree) after treatment has started, while others rarely, if 
ever, experience remission. Chronicity of depressive symptoms is associated with 
various comorbidities, such as personality, anxiety and substance use disorders. 
(41) Table 4 summarizes the full DSM-5 criteria for depression.
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Table 4: Classification of major depressive disorder according to the DSM-5 criteria. 
Major depressive disorder
A. Five (or more) of the following symptoms have been present during the same 
  2-week period and represent a change from previous functioning; at least one 
  of the symptoms is either (1) depressed mood or (2) loss of interest or 
  pleasure.
1. Depressed mood most of the day, nearly every day, as indicated by 
       either subjective report (e.g., feels sad, empty, hopeless) or observation 
made by others (e.g., appears tearful). 
2. Markedly diminished interest or pleasure in all, or almost all, activities 
most of the day, nearly every day (as indicated by either subjective 
account or observation)
3. Significant weight loss when not dieting or weight gain (e.g., a change 
of more than 5% of body weight in a month), or decrease or increase in 
appetite nearly every day.
4. Insomnia or hypersomnia nearly every day.
5. Psychomotor agitation or retardation nearly every day (observable by 
others, not merely subjective feelings of restlessness or being slowed 
down).
6. Fatigue or loss of energy nearly every day.
7. Feelings of worthlessness or excessive or inappropriate guilt (which may 
be delusional) nearly every day (not merely self-reproach or guilt about 
being sick).
8. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others).
9. Recurrent thought of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or a specific plan 
for committing suicide.
B. The symptoms cause clinically significant distress or impairment in social, 
  occupational, or other important areas of functioning.
C. The episode is not attributable to the psychological effects of a substance or 
  to another medical condition.
D. The occurrence of the major depressive episode is not better explained by 
  schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional 
  disorder, or other specified and unspecified schizophrenia spectrum and 
  other psychotic disorders.
E. There has never been a manic episode or hypomanic episode.
Although DSM categories are of great use in clinical practice, they have 
arbitrary boundaries, and show much overlap and comorbidity. Moreover, high 
heterogeneity of symptoms and severity within one diagnostic category (i.e. major 
depressive disorder) is possible. (42) Consequently, studying depression using 
the DSM-5 criteria provides a rather heterogeneous sample of patients. Current 
research, followed by the DSM-5 criteria, suggests that it may be more appropriate 
to study dimensions of psychopathology taking the multidimensionality of 
symptomatology into account, rather than using dichotomous DSM-5 categories. 
(40, 43)
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 1.2.3 Depression pathophysiology
Several hypotheses have been postulated for the pathophysiology of depression, 
which are not mutually exclusive. (44) Major depressive disorder is likely to have 
several causes. The monoamine-deficiency hypothesis describes depression as 
a disbalance in the function of the noradrenergic and serotonergic systems. The 
second hypothesis describes the role of stress and the hypothalamic-pituitary-
adrenal axis (HPA-axis). The role of cortisol and its central releasing factor, 
CRH, in depression has convincingly been described. (45, 46) Still, a single test 
for the cortisol level in the blood does not provide a diagnosis of depression, 
since sensitivity and specificity of the cortisol awakening curve are insufficient. 
Alternative biological theories of the pathophysiology of depression focus on 
altered glutamatergic neurotransmission, reduced GABAergic neurotransmission 
and abnormal circadian rhythms. (44) 
 1.2.4 Depression genetics
The estimated heritability for major depression is 37%, comparing monozygotic 
and dizygotic twins. (47) After years of genetic research, it has become clear 
that depression is not caused by any single gene but, like migraine, is caused 
by a complex interaction between multiple genes and the environment. Neither 
linkage nor genome-wide association studies showed clear associations for 
depression which could be replicated in independent studies. (48) The impressive 
amount of negative findings, however, imparts important lessons. First, due to 
the heterogeneity of undifferentiated depression, success of the GWAs approach 
will depend on very large sample sizes. Second, concentrating on subtypes 
or dimensions of depression will probably be more successful. Considering 
depression as a quantitative trait, or focusing on subgroups with certain comorbid 
disorders, could also increase the probability of significant findings.  Altogether, 
the difficulties of sample size and clinical differentiation are unavoidable if we 
want to find genetic clues to explain the pathophysiology of depression. (48)
 1.2.5 Depression treatment 
The first-line pharmacological treatment of depression is following a stepped-care 
principle, starting with a selective serotonin reuptake inhibitor (SSRI), which in case 
of non-response after 4 weeks should be changed to another SSRI or a serotonin-
norepinephrine reuptake inhibitor (SNRI). In case of non-response after 4 weeks, 
treatment should be changed to a tricyclic antidepressant (TCA). The next step 
is addition of lithium, after which it could be changed for a monoamine-oxidase 
inhibitor (MAO-inhibitor). As a last step in case of treatment resistant depression, 
electroconvulsive therapy (ECT) should be considered. (49) Psychotherapeutic 
interventions can be offered to patients with a mild or moderate depression. 
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Examples of effective psychotherapeutic interventions are cognitive behavioural 
therapy, interpersonal psychotherapy or psychodynamic psychotherapy. 
 1.3 Migraine and depression
 1.3.1 Comorbidity
Comorbidity was defined in 1970 by Feinstein as ‘any distinct additional clinical 
entity that has existed or that may occur during the clinical course of a patient who 
has the index disease under study’. (50) In this definition, the term comorbidity 
could be used for any entity that occurs before the diagnosis, during the disease, 
or after treatment of the disease. Even ‘non-disease’ clinical entities such as 
pregnancy or dieting were included by Feinstein’s definition. Nowadays, the term 
comorbidity is used mostly for associations between disorders that are greater 
than could be expected based on the usual individual prevalence of both diseases 
in the given population. 
 1.3.2 Migraine-specific comorbidities
The number of suggested comorbidities of migraine as reported in scientific 
literature has increased immensely over the past decades. Research into 
comorbidity and its underlying mechanisms has become increasingly interesting, 
as it might offer new insights in migraine pathophysiology. Furthermore, migraine 
patients presenting at headache clinics or general neurology practices, will 
often show multiple problems. (51) Knowledge about and recognition of this 
phenomenon has grown amongst clinicians. Still, the clinical comorbidities create 
new challenges for patient management, education, and treatment. From a 
scientific point of view population-based studies may be preferable when studying 
the prevalence of comorbid disorders in migraine. However, clinical studies may 
shed light on detailed cause-consequences of comorbidities, or influence on 
comorbidities when starting treatment for one of them.
Amongst the most reported migraine comorbidities, clear associations in 
population studies have been reported for ischemic stroke, epilepsy, vertigo, 
psychiatric diseases, sleep disorders, and pain disorders. However, most studies 
are cross-sectional, making causal interpretation of the results impossible. Only 
when prospective cohort studies have been done, in which the first onset of disease 
in a given population with another disease has been studied, firm statements on 
causality can be made. The best example in the field of migraine comorbidity is 
the relationship between migraine and depression, as described below: not only 
first onset of depression is increased in migraineurs, but also first onset migraine 
is increased in depressive patients. (52-54) This has led to the recognition of 
bidirectional comorbidity, possibly due to shared genetic factors. (55, 56)
  1
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 1.3.3 Interpretation of comorbidity
The interpretation of comorbidity is not always simple. In fact, true comorbidity 
can be caused by different mechanisms (figure 1). The first mechanism is that there 
is a unidirectional causation, which states simply that migraine may be a risk factor 
for another disease. In this case, it would be predicted that migraine would occur 
first. Secondly, when not only migraine increases the risk for a certain disease but 
also vice versa (the disease increases the risk for migraine either), this is called 
‘bidirectional comorbidity’. Such a bidirectional relationship is strongly suggestive 
for shared (environmental and/or genetic) risk factors. In diseases where 
genetic factors unmistakably play a role, the shared genetic factors hypothesis 
is particularly attractive. (57) Classical twin studies can be used to test whether 
shared genetic and/or environmental factors underlie the two disorders (58) but 
also direct identification of genetic factors can be successful when studying cases 
with both disorders. As a third mechanism of comorbidity, migraine is part of the 
clinical spectrum of a clear monogenetic disease. 
This discussion of comorbidity started with migraine. Of course, a discussion 
starting with depression would go along the same lines.
 1.3.4 Why study the comorbidity of migraine with depression?
Understanding the associations between migraine and psychiatric disorders is 
important for various reasons. Migraine and depression are both ranked in the 
top-10 of disorders with high disability and burden. (2) The presence of psychiatric 
conditions, especially depression, is a risk factor for migraine chronification. (32) In 
addition, comorbid migraine is associated with poorer functioning and increased 
somatic complaints in depressed patients. (59) Migraine patients with comorbid 
psychiatric disorders are greater consumers of health resources than migraineurs 
without psychiatric conditions. (60) Lastly, treatment choices for both migraine 
and psychiatric disorders can be influenced by the presence of comorbidity. 
Prescription of beta-blockers is (although debated) relatively contraindicated as 
migraine prophylactic in patients with comorbid depression. Migraine prophylaxis 
with SSRIs is still controversial because of the suggested risk of developing a 
serotonin syndrome when prescribed together with triptans, especially when used 
frequently. In our experience this is, however, not a problem in practice, as long 
as triptans are not overused, i.e. more frequently than on 2 days per week on a 
regular basis. Valproate as prophylactic treatment for migraine may be favoured 
due to its stabilising effect on the mood.
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Figure 1: Mechanisms of comorbidity
    1: Unidirectional causation
    2: Bidirectional comorbidity, due to shared (environmental or genetic) risk factors
    3: Monogenetic disease theory
 1.3.5 What is known about migraine and depression comorbidity?
Although it seems logical that persons with chronic, unpredictable headaches 
get depressed, which often is stated by patients and their family and friends, the 
association is bidirectional. Also persons with a depression show an increased 
risk of getting migraine. Population based studies have shown that persons with 
a lifetime history of depression have an increased risk to develop migraine later 
during life when compared with persons without a lifetime depression (OR 3.0, 
95% CI 1.2-7.6). Vice versa, persons with migraine have an increased risk of first 
onset major depression, compared with persons without migraine (OR 5.2, 95% 
CI 2.4-11.3). (53, 54) Such bidirectional association suggests a shared aetiology, 
which, according to several studies, is at least partly explained by genetic factors. 
(61-63) Indeed, evidence suggests that migraine and depression share genetic 
factors. In a large twin study, 20% of the variability of comorbid migraine and 
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shared environmental factors. (56) A study performed in a genetically isolated 
Dutch population investigated the extent to which the comorbidity of migraine 
and depression could be explained by shared genetic factors. Clear indications 
were found for shared genetic factors in depression and migraine, especially in 
migraine with aura. (55) It is still unclear to what extent the comorbidity of migraine 
with depression also counts for a monogenic form of migraine with hemiplegia 
during the aura phase, Familial Hemiplegic Migraine (FHM). Also, the question 
which specific genetic factors are involved in the increased liability to both 
disorders, remains open.
 1.3.6 The migraine triad: chronification, depression, and medication overuse
Comorbid depression is particularly common in chronic migraine patients. (64) 
Depression is also an important predictor of medication overuse, which is seen in 
up to half of persons with chronic migraine. (65) Depression is considered a major 
risk factor for migraine chronification. (32) Furthermore, overuse of analgesics is 
associated with an increased risk of depression. (66) Comorbid depression is thus 
likely to increase the risk of chronification in migraine and complicate treatment. 
(67-69) In addition, comorbid migraine is associated with poorer functioning and 
increased somatic complaints in depressed patients. (59) Altogether, a triad has 
been suggested of migraine chronification, medication overuse and depression. 
It is unclear to which extent genetic factors, general determinants and migraine 
specific factors are involved in this migraine triad. 
 1.3.7 Depression and cluster headache
Another important question is whether the triad of chronification of attacks, 
medication overuse and depression is specific for migraine. Hitherto, most studies 
about headache and depression are about migraine. One of the questions 
remaining is whether depression also is comorbid with cluster headache, another 
type of primary, severe, paroxysmal headache.  This question is in particular 
important, as the severity of the pain has earned cluster headache the title ‘suicide 
headache’. Suicidal tendencies have been reported in 25-55% of cluster headache 
patients. (70-72)
Cluster headache has, especially when compared with migraine, a low prevalence 
of one in 1000 with a male to female ratio of 4:1. (73, 74) The impact of cluster 
headache on quality of life, social functioning, and socioeconomic status can be 
enormous. (75)
Typical attacks of cluster headache consist of severe, strictly unilateral pain which is 
orbital, supraorbital, temporal or in any combination of these sites, lasting 15-180 
minutes and occurring from once every other day to eight times a day. The pain 
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is associated with ipsilateral conjunctival injection, lacrimation, nasal congestion, 
rhinorrhoea, forehead and facial sweating, miosis, ptosis and/or eyelid oedema, 
and/or with restlessness or agitation. (8) In about 85% of patients, attacks are 
clustered in periods of several weeks to months, alternating with attack-free 
periods of several months to years (episodic cluster headache); in the remaining 
patients, long attack-free periods are absent (chronic cluster headache). (73, 76)
As cluster headache shows several clinical, therapeutical, and pathophysiological 
similarities to migraine, and studies on the comorbidity of cluster headache 
with depression are lacking, the question remains whether depression is also a 
comorbid condition in cluster headache.
1.4 Scope of the thesis
In this thesis different components of the migraine triad of chronification, 
depression, and medication overuse are investigated. The thesis pays attention 
to epidemiological aspects of the triad (chapters 2-5), to clinical implications and 
applications of the triad (chapter 6), to genetic aspects of migraine chronification 
(chapter 7) and to a comparison with a different type of primary headache, cluster 
headache (chapter 8).
In chapter 2, we aim to further elucidate the association between migraine and 
depression and to identify migraine specific factors associated with depression. 
In chapter 3, we assess cutaneous allodynia as a possible predictor of migraine 
chronification, as it is known as a factor which is involved both in migraine frequency 
and comorbidity with depression. In chapter 4, we analyse the prevalence of lifetime 
depression in a large cohort of patients with FHM. Chapter 5 describes whether 
migraine patients display different symptoms patterns of affective disorders than 
healthy controls, and persons with a current or past affective disorder. In chapter 
6, we focus on the chronification part of the triad by investigating the role of 
the headache nurse in detoxification of acute headache medication. Chapter 7 
describes a genetic association study for migraine chronification. In chapter 8, we 
want to assess whether depression is also comorbid in cluster headache, and to 
identify cluster headache specific characteristics that might be associated with 
depression. Chapter 9 provides a general discussion of the thesis, reviewing the 
results and discussing future possibilities for research.
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Abstract
Introduction
There is a strong association between migraine and depression. The aim of this 
study was to identify migraine specific factors involved in this association. 
Methods
We conducted a cross-sectional study in a large well-defined cohort of migraine 
patients (n=2533). We assessed lifetime depression using validated questionnaires, 
and diagnosed migraine based on the International Classification of Headache 
Disorders III-beta criteria. Multivariate regression analyses were conducted.
Results
Of the 2533 migraineurs that were eligible, 1137 (45%) suffered from lifetime 
depression. The following independent factors were associated with an increased 
depression prevalence: i) migraine specific risk factors: high migraine attack 
frequency, the presence of allodynia, ii) general factors: being a bad sleeper, 
female gender, high BMI, being single, smoking, and a low alcohol consumption. 
Conclusion
This study identified allodynia, in addition to high migraine attack frequency, as a 
new migraine specific factor associated with depression. 
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Introduction
Migraine and depression both rank among the most prevalent and disabling 
disorders and show a bidirectional increased comorbidity. (1-4) Such bidirectional 
association suggests a shared aetiology, which is at least partly explained by 
genetic factors. (5, 6)
Comorbid depression seems to be particularly common in chronic migraine 
patients. (7) Depression is also an important predictor of medication overuse, 
which is seen in up to half of persons with chronic migraine. (8) Comorbid 
depression is thus likely to increase the risk of chronification in migraine and to 
complicate treatment. (9-11) In addition, comorbid migraine is associated with 
poorer functioning and increased somatic complaints in depressed patients. 
(12) Altogether, a triad is suggested of migraine chronification, depression 
and medication overuse. Identifying migraine specific factors associated with 
depression will help to detect patients that are at an increased risk of depression 
and chronification. 
The aim of this study was to further elucidate the association between migraine 
and depression in a large, well-defined, web-based migraine cohort and to identify 
migraine specific factors associated with depression.
Methods
Participants and procedures
Our study was conducted as a part of the LUMINA project. (13)  Participants of 
the LUMINA project were Dutch adults aged 18 to 74 years with migraine with or 
without aura according to the International Classification of Headache Disorders 
criteria (previously ICHD-II, now ICHD-III beta version). The LUMINA project was 
approved by the medical ethics committee of the Leiden University Medical 
Centre. All subjects provided written informed consent prior to the study. For a 
further description of the participants and procedures, see Supplementals.
Measures
Lifetime depression was measured, using validated cut-off scores on depression 
questionnaires and additional questions on lifetime depression. (14, 15) 
Cutaneous allodynia was measured using the 12-item Allodynia Symptom 
Checklist. The Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep 
disturbances during the month before assessment. (16) For a further description 
of the measures, see Supplementals. 
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Data analysis
Logistic regression analyses were used to test which variables were associated with 
lifetime depression among migraine patients. For all analyses p-values of <0.05 
were considered to indicate statistical significance. For an extended description 
of the data analyses, see Supplementals. 
Results
Study population and descriptive statistics
The total study flow is shown in supplemental fig. 1. In total, 3624 migraineurs 
within the LUMINA project were sent a depression questionnaire (mean age: 
41.7 ± 11.9), based on migraine diagnosis and the presence of written informed 
consent. In total 3177 (87.7%) returned this depression questionnaire. Because of 
missing data, 2533 were eventually included in the analysis. 
Comparison of included vs. excluded participants showed for all analyses that 
included participants were slightly older and had more often migraine with aura, 
but did not differ in gender (data not shown). Of the 2533 migraineurs that were 
eligible 1137 (45%) suffered from life time depression. A total of 1767 migraine 
patients (70%) suffered from allodynia during migraine attacks.
Correlates of depression in migraine patients
The comparison for migraine patients with depression versus those without 
depression is  shown in Table 1. The results of the initial univariate analyses are 
shown in Table 2 (left part). Significant univariate associations with depression 
were found for the following migraine specific variables: attack frequency, number 
of migraine days, use of prophylactic medication and allodynia. Other statistically 
significant variables were being a bad sleeper, gender, BMI, level of education, 
marital status, smoking, and alcohol consumption. These variables (except 
number of migraine days, because of the high correlation with migraine attack 
frequency) were entered together in a multivariate logistic regression analysis. 
The results of this analysis (Table 2, right part) showed the following independent 
factors associated with depression in migraine patients; i) the migraine specific 
factors: high migraine attack frequency, allodynia, ii) the general factors: being 
a bad sleeper, female gender, high BMI, being single, smoking, and alcohol 
consumption.  
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Discussion
This large-scale study in a well-defined migraine cohort showed that depression 
is associated with allodynia and high attack frequency in migraine patients. Our 
study is the first large, web-based study to show that allodynia is associated with 
an increased prevalence of depression in migraine patients. Previous studies 
investigated the reversed association, namely that the risk of allodynia is higher 
among migraine patients with depressive symptoms. (17, 18) One recent, 
small clinic-based study showed that the severity of cutaneous allodynia was 
associated with current mood status, but did not focus on lifetime depression. 
(19) Thus, according to our study and others, migraine, depression and allodynia 
are intertwined. In a previous study we showed that allodynia (and depression) 
make a migraine patient vulnerable for migraine chronification. (20) Since 70% 
of migraineurs suffer from allodynia, the clinical impact of this finding might be 
limited. However, the pathophysiological role of allodynia in migraine chronification 
and the migraine-depression association is of great importance. Allodynia is 
considered as a clear marker for a central sensitization process of the brain. (21) 
Central sensitization is an activity-dependent functional plasticity that results from 
post-translational regulation and transcriptional regulation of key gene products. 
(22) Once established, sensitization of second order trigeminovascular neurons 
becomes activity independent, and maintains itself in the absence of sensory input 
later on. Clinically, central sensitization causes refractoriness to acute treatment. 
(21) Thus, allodynia has consequences for disease progression and treatment, 
and it should lead to an increased awareness of comorbidity of migraine and 
depression, and of risk of chronification of migraine. Pathophysiologically, the triad 
migraine, depression and allodynia may suggest a self-reinforcing dysfunction of 
CNS structures involved in the modulation of neuronal excitability and pain. 
Poor sleep quality in migraine patients was associated with higher odds of 
depression. Whereas the hypothalamus is supposedly involved in migraine, 
depression, and sleep disorders, the association between these three disorders 
is suggestive of hypothalamic modulation of the trigeminovascular pathway. (23) 
Pain signals that originate in the trigeminovascular pathway can alter the activity 
of hypothalamic and limbic structures that integrate sensory, physiological and 
cognitive signals that drive behavioural, affective and autonomic responses. (24) 
The strengths of this study are the large sample size, the well-defined migraine 
status and detailed information on depression characteristics. Most importantly, 
this is one of the first studies demonstrating that cutaneous allodynia and sleep 
disturbances are strongly associated with depression in migraineurs. Possible 
limitations include the fact that our population might be younger and higher 
educated than the migraine population in general due to the recruitment of patients 
via the internet. However, we tried to limit this effect by enabling participants to fill
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out the questionnaires on paper. The cross-sectional nature of this study prevented 
us from drawing conclusions about causality in the relationship between high 
attack frequency, allodynia, sleep disturbances and depression. 
In summary, frequent attacks and allodynia are associated with a higher prevalence 
of depression in migraine patients. Future research should focus on identifying 
pathophysiological mechanisms linking migraine and depression.
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Tables and figures
Table 1: Baseline characteristics LUMINA population of 2533 migraine patients, separated 












 1-2 attacks per year
 3-6 attacks per year
 7-12 attacks per year
 13-54 attacks per year
 more than 54 attacks per year
Number of migraine days
 1-2 days per year
 3-6 days per year
 7-12 days per year
 13-54 days per year
 more than 54 days per year
Use of acute medication
 no
 yes, if attack
 yes, (almost) daily
Use of a triptan (yes)






Years of fulltime education
Marital status
 Single
 Cohabiting / married
 Divorced / widowed
Smoking packyears
Caffeine consumption (ie per day)
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BMI, body mass index; MO, Migraine without aura; MA, Migraine with aura.
Values are the absolute numbers with corresponding percentages or means ± SD.
Few (n=35) patients reported more than one attack on one day, probably because migraine 
recurrences were counted as new attacks
  2















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Our study was conducted as a part of the LUMINA project. (13) Participants of 
the LUMINA project were Dutch adults aged 18 to 74 years with migraine with or 
without aura according to the International Classification of Headache Disorders 
criteria (previously ICHD-II, now ICHD-III beta version). 
Our LUMINA study population was invited via the lay press nationwide to enroll 
via the especially designed, nation-wide LUMINA website. Additionally, patients 
from our outpatient headache clinic were invited by a letter. This group however, 
comprises only 3.5% of the total LUMINA population. On the website, patients 
were asked to fill out a screening questionnaire that has been validated previously. 
(25) Firstly, if patients fulfilled the screening criteria, they were sent a web-based 
extended migraine questionnaire, based on the ICHD-II criteria (now ICHD-
III beta). (14, 15, 26) This questionnaire was validated by performing a semi-
structured telephone interview in 1038 patients who had filled out the extended 
migraine questionnaire. (13) The specificity of the questionnaire was 0.95. In 
addition to questions that were necessary to diagnose migraine accurately, the 
extended questionnaire also included items on demographic factors, acute and 
prophylactic headache medication use, migraine attack frequency and migraine 
days, and allodynia (the experience of pain due to stimuli that do normally not 
provoke pain). Participants without the needed internet skills were able to fill out 
the questionnaires on paper.
Secondly, a web-based questionnaire on symptoms of (lifetime) depression 
was submitted to all migraine patients (n=3624). This depression questionnaire 
consisted of the Hospital Anxiety and Depression Scale (HADS-D), the Centre 
for Epidemiologic Studies Depression Scale (CES-D) and additional questions 
on lifetime depression: ‘Have you ever used anti-depressants, prescribed for a 
depression?’ and ‘Have you ever been diagnosed with a depression’? (14, 15) Lastly, 
a questionnaire was sent to all participants for details on sleeping disturbances, to 
be able to adjust for the potential confounding effect of sleep in the relationship 
between migraine and depression.
The LUMINA project was approved by the medical ethics committee of the Leiden 
University Medical Centre. All subjects provided written informed consent prior to 
the study.
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Measures
Lifetime depression diagnoses were based on extended and validated 
questionnaires, according to the International Classification of Headache Disorders 
(previously ICHD-II, now ICHD-III beta version). (13, 25, 26) Migraine frequency 
was measured both as attacks per year and as migraine days per year, using 5 
categories: 1-2 attacks/days per year, 3-6 attacks/days per year, 7-12 attacks/days 
per year, 13-54 attacks/days per year, more than 54 attacks/days per year.  
Lifetime depression was measured as a dichotomous variable. We used validated 
cut-off scores, in combination with a previously used and published algorithm 
for depression and an additional question on lifetime depression: (lifetime 
depression = HADS-D ≥ 8 or CESD ≥ 16 or use of antidepressants (prescribed 
for a depression) or diagnosis depression). (6, 14, 15) Although the HADS-D 
(depression subscale of the HADS) and CESD questionnaires focused only on 
the previous two weeks, we aimed to reliably measure lifetime depression by 
adding questions on antidepressant use and depression diagnoses. Validation 
of the resulting compound depression diagnoses by performing a telephonic 
Composite International Diagnostic Interview (CIDI) in a subset of 102 randomly 
selected patients showed a sensitivity of 78% and a specificity of 64% for DSM-IV 
classified depression. (27) 
To assess cutaneous allodynia, the 12-item Allodynia Symptom Checklist (ASC) 
was used. (17) The ASC was modified to include dichotomous answer options 
(‘yes’ and ‘no’), which could be counted up to an allodynia score (range: 0-12). If 
participants scored two points or more they were classified as having allodynia. 
To be able to correct for the potential confounding effect of sleep disorders and 
possible poor sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used to 
measure sleep disturbances during the month before assessment. (16) The PSQI 
is designed to measure the quality and patterns of sleep in the past month and 
contains 19 self-rated questions, with a global scoring range of 0 to 21. Higher 
scores denote a poorer sleep quality. A validated cut-off score of ≥5 was used to 
separate ‘good sleepers’ from ‘bad sleepers’.
Data analysis
Baseline characteristics were reported as mean (SD) or percentages. Differences in 
means between groups were tested with independent samples t-tests. Differences 
in proportions were tested by x² tests. To determine migraine specific  and general 
determinants of depression, a logistic regression model with lifetime depression as 
the outcome was developed, using a two-step procedure. First, univariate logistic 
regression analyses were used to test which potential predictors were associated 
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with lifetime depression among migraine patients. The following variables were 
included in the univariate model as migraine specific determinants: age at onset 
(migraine), migraine subtype, migraine attack frequency, number of migraine 
days, use of acute medication, use of a triptan, use of prophylactics and allodynia. 
The following variables were included as general determinants:, gender, age, 
BMI, educational level, marital status, smoking, caffeine consumption,  alcohol 
consumption, and sleeping disturbances. Second, all predictors with a statistically 
significant univariate effect were entered in a multivariate logistic regression 
model. Results were reported as odds ratios with 95% confidence intervals (CI) 
and corresponding p-values.
For all analyses p-values of <0.05 were considered to indicate statistical significance. 





 Depression data available 
n = 3177 (87.7%)
Suitable for analysis 
n = 2533 (69.9%)
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Summary
Objectives
Cutaneous allodynia is a common feature accompanying migraine attacks and 
considered a clinical marker for central sensitization. In a longitudinal study, we 
wanted to investigate if allodynia in migraine patients is a predictor of increasing 
frequency of migraine days. 
Methods 
We included 3,029 well-defined, web-based migraine patients (86% female, mean 
age 42.8 ± 11.4 years, 61% migraine without aura). Questionnaires on migraine 
characteristics (including allodynia), depression and demographic factors were 
applied. The number of migraine days was measured twice. Multivariate regression 
models were used, with correction for other factors that are involved in the relation 
between allodynia and the number of migraine attacks or migraine days, with 
specific focus on depression.
Results 
Of all 2,331 eligible migraine patients 1,624 (70%) had allodynia. Lifetime 
depression was an independent risk factor for allodynia (OR 1.52, 95% CI 1.26-
1.84), as well as female gender, low age at onset, and high migraine attack 
frequency. Analysis of the longitudinal data (in migraineurs with a follow-up 
period of >6 months) showed that, apart from the known risk factors (low age 
at onset, high baseline number of migraine days, and depression), allodynia was 
an independent predictor for increase in number of migraine days over a mean 
follow-up period of 93 ± 30 weeks (median: 103 weeks, range: 26 – 160 weeks).
Conclusions 
Cutaneous allodynia is a risk factor for migraine chronification and may warrant 
preventive treatment strategies.
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Introduction
Cutaneous allodynia, the perception of pain in response to non-noxious stimuli to 
the normal skin, is a common feature accompanying migraine attacks. Migraine 
patients experience an increased sensitivity of the skin for common daily activities 
during attacks, such as combing of hair, taking a shower, touching the periorbital 
skin, shaving, or wearing earrings during migraine attacks. (1, 2) Prevalence 
estimates of allodynia in migraine patients range from 50 to 80%. (3)
Three distinct forms of allodynia have been described: thermal, static mechanical 
and dynamic mechanical allodynia. (4) Furthermore, a distinction between cranial 
and extra-cranial allodynia can be made. Allodynia is a marker for sensitization of 
nociceptive neurons in the trigeminal nucleus caudalis, which receive convergent 
input from the dura mater and the peri-orbital skin. (5) During a migraine attack, 
central sensitization of trigeminal neurons is elicited by persistent pain through 
activation of meningeal perivascular pain fibers. As a result of this sensitization, 
non-noxious stimuli of the peri-orbital skin are perceived as painful. Allodynia is 
a hallmark for success rate of acute headache medication treatment, because the 
success rate of rendering migraine patients pain-free increases dramatically if 
medication is taken before the establishment of allodynia and central sensitization. 
(6) Factors that have been reported to increase the likelihood of having allodynia 
during migraine attacks are: female gender, high Body Mass Index, headache 
specific features such as a low age at onset, high frequency of attacks, and 
comorbidity with depression and anxiety. (1, 2, 7-10) Extensive evidence is 
available on the comorbidity of migraine with depression, suggesting associations 
between migraine chronification, depression and medication overuse. (11-13) 
Because allodynia may be involved in these associations we evaluated the specific 
relationship between allodynia, depression and total migraine days in a large well-
defined, web-based population of migraine patients. (14) This is the first study 
to assess if allodynia is an independent predictor of (i) migraine chronification 
(increase of the average number of migraine days per month) and (ii) overuse of 
acute headache medication.
Methods
Study design and population
Our study was conducted as a part of the LUMINA project, the details of which 
are reported elsewhere. (15) Participants were Dutch adults aged 18 to 74 years 
with migraine with or without aura according to the International Classification 
of Headache Disorders (ICHD-II) criteria. Our LUMINA study population was 
recruited via a dedicated, nation-wide website inviting migraineurs to participate 
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in migraine research. In addition, patients attending our dedicated headache clinic 
were also invited to participate in this survey. This group, however, comprises only 
3.5% of the total LUMINA population.  On the website, patients were asked to 
fill out a screening questionnaire that has been validated previously. (16) Firstly, 
if patients fulfilled the screening criteria, they were sent a web-based extended 
migraine questionnaire, based on the ICHD-II criteria. (15, 17) This questionnaire 
was validated before by performing a semi-structured telephone interview in 1038 
patients who had filled out the extended migraine questionnaire. (15) The specificity 
of the questionnaire was 0.95. In addition to questions that were necessary to 
diagnose migraine accurately, the extended questionnaire also included items on 
demographic factors, acute and prophylactic headache medication use, migraine 
attack frequency and migraine days, and allodynia. Participants without the needed 
internet skills were able to fill out the questionnaires on paper.
Secondly, all applicable migraine patients (n=3029) were selected for a web-
based questionnaire on symptoms of (lifetime) depression. This depression 
questionnaire consisted of the Hospital Anxiety and Depression Scale (HADS-D), 
the Centre for Epidemiologic Studies Depression Scale (CES-D) and additional 
questions on lifetime depression: ‘Have you ever used anti-depressants with as 
indication depression?’ and ‘Have you ever been diagnosed with a depression’? 
(18, 19) Only after having filled out the complete depression questionnaire, 
patients were enrolled in this study.
Thirdly, a questionnaire was sent to a large subset of participants for follow-up 
details on migraine days (defined as number of migraine headache days per 
month) and medication use. This allowed us to perform a longitudinal analysis on 
migraine days. Questions on demographic factors were part of this questionnaire. 
For the longitudinal analysis on migraine days only participants with a follow-up 
time of more than 6 months were selected (mean 93 ± 30 weeks, median 103 
weeks, range: 26 – 160 weeks).
This LUMINA project was approved by the medical ethics committee of the Leiden 
University Medical Centre. All subjects provided written informed consent prior to 
the study.
Measurements
The extended migraine questionnaire included a 12-item questionnaire on 
symptoms of cutaneous allodynia (CA). These 12 items were similar to the items 
of the validated Allodynia Symptom Checklist (ASC). (2) CA was measured as 
a continuous variable, counting up the scores of all 12 allodynia items for each 
patient. Herewith “yes” was scored as 1, and “no”, “not applicable” and “unknown” 
were scored as 0. Secondly, based on this continuous scale, we divided CA into 
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2 categorical classes, in concordance with the ASC. (2) Migraine patients were 
scored as allodynic when answering “yes” on ≥ 2 CA items. Exploratory cluster 
analysis was performed to determine whether the 12 items would fit in the known 
CA subgroups: thermal, static mechanic and dynamic mechanic. The analysis 
showed the expected clustering of i) resting the head on a pillow, exposure to 
heat and exposure to cold (thermal allodynia); ii) taking a shower, shaving the face 
and combing the hair (dynamic mechanic allodynia); iii) wearing contact lenses, 
wearing glasses, wearing a pony tail, wearing tight clothes, wearing earrings 
and wearing a necklace (static mechanic allodynia). This confirmed that our 
questionnaire, which was adapted from the ASC, covered well the construct of CA.
Lifetime depression was measured as a dichotomous variable. We used validated 
cut-off scores, in combination with a previously used and published algorithm 
for depression and an additional question on lifetime depression: (Lifetime 
Depression = HADS-D ≥ 8 OR CES-D ≥ 16 OR use of antidepressants (with 
indication depression) OR diagnosis depression). (18-20) Although the HADS-D 
(depression subscale of the HADS) and CESD questionnaires focused only on 
the previous two weeks, we aimed to reliably measure lifetime depression by 
adding questions on antidepressant use and depression diagnoses. Validation of 
the depression diagnoses by performing a telephonic Composite International 
Diagnostic Interview (CIDI) in a subset of 102 randomly selected patients showed 
a sensitivity of 78% and a specificity of 64%. (21)
At baseline, we measured migraine frequency in two ways: number of migraine 
attacks and number of migraine days. For both we used five frequency classes, 
ranging from ‘1-2 per year’ to ‘more than 54 per year’. On follow-up we only 
assessed number of migraine days as continuous variable. We did this for two 
reasons: 1) definition of CM is arbitrary with cut off values of ≥ 15 headache days 
and ≥ 8 days migraine, 2) for purposes of statistical power (increased power when 
using continuous outcome measurement). (22) To assess change in migraine days 
over the follow-up period, we transformed the frequency classes at baseline into a 
continuous variable by using for each bracket the mean number of migraine days 
(i.e. 1-2 days per year -> 1,5 day per year). This was subtracted from the number of 
migraine days at follow up to obtain a continuous variable for change in number 
of migraine days per month.
In the follow-up measurement, patients were asked to fill in the number of days on 
which they had taken acute migraine medications like triptans and painkillers such 
as simple analgesics or NSAIDs for headache during the past 3 months.
Data analysis and statistics
Baseline characteristics were reported as mean ± standard deviations (SD) 
or percentages. Differences in means between groups were tested with 
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independent samples t-tests. Differences in proportions were tested using x2 
tests. Multivariate logistic regression models were used to test the association 
between CA and the following determinants: gender, age, BMI, age at onset of 
migraine, migraine subtype, the use of prophylactics, migraine attack frequency 
(categorical) and depression. Supplementary analysis was performed with 
migraine duration as substitute for age at onset. Results were reported as odds 
ratios with 95% confidence intervals (CI) and corresponding p-values. To test 
whether the association with migraine attack frequency differed between patients 
using prophylactics and patients not using prophylactics, the interaction between 
migraine attack frequency and prophylactics was added. To test whether the 
associations between CA and depression differed between males and females, 
the interaction between depression and gender was added. 
Determinants of migraine days and number of medication days at follow-up 
were investigated using univariate and multivariate linear regression models. 
Because of the expected left-skewed distribution of migraine days, we used a log-
transformation of this measure to prevent a skewed distribution of the residuals 
in the model. Determinants of change in migraine days were investigated using a 
multivariate linear regression model. For all models the following covariates were 
included: gender, age, BMI, age at onset of migraine, allodynia, migraine subtype, 
use of prophylactics, number of migraine days at baseline (categorical), depression 
and time of follow-up. Supplementary analyses were performed with migraine 
duration as substitute for age at onset. Results were reported as log-transformed 
regression coefficients (exp(B)) with 95% CI’s, standardized regression coefficients 
(Beta) and corresponding p-values.
For all analyses p-values < 0.05 were considered as statistically significant. All 
statistical analyses were performed using SPSS 17.0 (SPSS inc., IBM, USA). 
Results
The total study flow is shown in figures 1 and 2. Of 3029 migraine patients who 
were sent depression questionnaires, 2331 (77.0%) were suitable for primary 
analysis. Participating (n=2331) versus non-participating (n=698) migraine patients 
were slightly older (42.8 vs. 39.6 years, p<0.001) but did not significantly differ 
in gender or migraine subtype. A total of 1992 (65.8%) migraine patients were 
suitable for secondary analysis. Participating (n=1992) versus non-participating 
(n=1037) patients were again slightly older (43.0 vs. 40.4 years, p<0.001) but did 
not significantly differ in gender or migraine subtype. Table 1 displays all baseline 
characteristics of the sample suitable for primary analysis, divided by the presence 
of CA. 1,624 migraine patients (69.7%) suffered from CA during migraine attacks. 
Of 2331 migraine patients 1423 (61.0%) had migraine without aura, being equally 
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divided over the groups with and without allodynia. Migraine patients with CA 
were more often females, had lower age at onset, longer disease duration, higher 
migraine attack frequency, used more often prophylactic agents, and had more 
lifetime depression (table 1).
In the first part of the analyses, determinants of allodynia were examined in a 
multivariate logistic regression analysis (table 2). The following determinants 
were significantly associated with CA: i) female gender, OR = 2.98 (95% CI 2.33-
3.82); ii) lower age at onset, OR = 0.98 per year (95% CI 0.97-0.99); iii) longer 
migraine duration, OR = 1.02 per year (95% CI 1.01-1.03) iv) higher migraine 
attack frequency (for individual OR’s of all contrasts see table 2); and v) lifetime 
depression, OR = 1.52 (95% CI 1.26-1.84). Interaction terms migraine attack 
frequency*prophylactics and lifetime depression*gender were not significant; 
final analyses were run without interaction terms.
In the follow-up study, associations between CA at baseline and the (log-
transformed) number of migraine days at follow-up, with adjustment for several 
covariates were studied (table 3). The model showed that the following parameters 
were independent, statistically significant predictors for the number of migraine 
days at follow-up: i) having CA (p<0.001); ii) low age at onset (p=0.03); iii) higher 
migraine duration (p=0.03); iv) having migraine without aura (p=0.008); v) higher 
baseline number of migraine days (for individual p-values of all contrasts see table 
3); and vi) having lifetime depression (p<0.001). 
We studied the association between CA at baseline and the change in number of 
migraine days at follow up (mean duration of follow-up time was 93 ± 30 weeks, 
median: 103 weeks, range: 26 – 160 weeks). Table 4 presents multivariate linear 
associations between CA at baseline and the change in migraine days at follow-
up, with adjustment for several covariates. The model showed that the following 
parameters were independent, statistically significant predictors of an increase 
in migraine days: i) having CA (p<0.001); ii) lower age at onset (p=0.01); iii) 
higher migraine duration (p=0.01); iv) using prophylactics (p=0.05); v) having a 
depression (p=0.001). 
The association between CA at baseline and the (log-transformed) number of 
medication days at follow-up with adjustment for covariates are shown in table 5. 
The model showed that the following parameters were independent, statistically 
significant predictors for the number of medication days at follow-up: i) having CA 
(p=0.002); ii) low age at onset, (p=0.002); iii) higher migraine duration, (p=0.002); 
iv) using prophylactics, (p<0.001); v) higher baseline number of migraine days 
(for individual p-values for all contrasts see table 5); and vi) having a lifetime 
depression (p<0.001). 
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Discussion
This is the first longitudinal study demonstrating that cutaneous allodynia is 
an independent predictor of migraine chronification. Furthermore, we found 
independent associations of allodynia with several migraine specific determinants. 
Migraine patients are at increased risk of depression, and shared genetic factors 
may underlie this association. (20, 23) Comorbid depression is an important 
predictor of substance dependence and is very common in chronic migraine 
patients, in particular in those with overuse of acute headache medication. (24, 
25) Thus a triad between migraine chronification, depression and medication 
overuse is suggested. (11-13) In this triad, cutaneous allodynia (CA) plays a role. 
Our data show that depression and high migraine attack frequency (as a marker 
of chronification) are independently associated with CA. We hypothesized 
that recurrent migraine with CA lead to a decreased threshold for subsequent 
migraine attacks. This statement is supported by the following findings: i) the 
association between CA and high migraine frequency (measured as migraine 
attack frequency in the cross-sectional part of the study and measured as migraine 
days in the longitudinal part of the study); ii) the association between low age at 
onset and CA; and iii) longer migraine duration is associated with CA in the same 
magnitude as low age at onset.
The clinical findings from this study correspond with the pathophysiological 
mechanism of CA. The underlying mechanism of migraine and allodynia 
is activation of the trigeminovascular neurons. (26) The activation of the 
trigeminovascular pathway contributes: i) to the headache phase of the migraine 
attack by sensitization of peripheral trigeminovascular neurons innervating the 
meninges; ii) to the cephalic allodynia by sensitization of second-order neurons 
in the spinal trigeminal nucleus (in the medullary dorsal horn) that receive 
input form the meninges, scalp and facial skin; and iii) to the development of 
extracephalic allodynia by third-order neurons in the posterior thalamic nuclei 
which receive input form meninges, facial and body skin. (26) Importantly, once 
established, sensitization of second order trigeminovascular neurons becomes 
activity independent, and maintains itself in the absence of sensory input later on. 
(26) The activity-independent form is the consequence of neurotransmitter and 
neuromodulator induced activation of multiple intracellular signaling pathways. 
Activity-independent sensitization develops slowly over several hours and lasts 
for a prolonged period of time. (27) This has important clinical implications, as late 
treatment with triptans during an attack is unsuccessful when this independent 
activity has occurred. (6) Finding out which critical thresholds are exceeded before 
central sensitization occurs will potentially lead to new medications preventing 
sensitization. Analyses of differences in brain structure and function, biochemical 
markers, and genetic profiles between migraine patients with and without CA will 
further enlighten the basic mechanisms behind CA, migraine chronification and 
depression.
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A possible explanation for the association between CA and migraine frequency 
may be that repetitive activation of trigeminovascular neurons and consequently 
repetitive activation of modulatory pain pathways involving the periaqueductal gray 
may lead to impairment of function or neuronal cell damage in the periaqueductal 
gray (involved with migraine modulation) or eventually in other areas involved 
in migraine generation, thus leading to chronification of migraine. (1, 3) Another 
concept is that of nociception-induced plasticity, which has been demonstrated in 
animal experiments in the somatosenory cortex, thalamus, trigeminal brainstem 
neurons, and the cortico-limbic pathway. (28) This model suggests that kindling 
and related models of neuroplasticity can be used to describe ways in which 
exposure to a noxious stimulus may, under certain conditions, lead to a sensitized 
state, and to chronification of pain.
Triptan induced allodynia has been studied in rats, proposing a biological 
mechanism between increased frequency of headache following triptan use. (29) 
However, there is no evidence for this phenomenon in humans. In our study, there 
was no association between triptan use and allodynia (OR 1.07, 95% CI 0.87 – 
1.35). The potential role of hormonal use has not been investigated in this study.
Our study did not aim to define subjects as chronic migraineurs or episodic 
migraineurs. We measured the increase in the number of migraine days, as 
a marker of chronification. We did this for two reasons: 1) definition of CM is 
arbitrary with cut off values of ≥ 15 headache days and ≥ 8 days migraine, 2) for 
purposes of statistical power (increased power when using continuous outcome 
measurement). (22) We measured the average number of migraine attacks in the 
baseline measurement, whereas each migraine attack represents one occurrence 
of allodynia, independent from the duration of the attack.
The strengths of this study are the large sample size, the well-defined migraine 
status and detailed information on allodynia and depression characteristics. Most 
importantly, this is the first longitudinal study demonstrating that allodynia is a 
risk factor for migraine chronification. Possible limitations include the fact that our 
population might be younger and higher educated than the migraine population 
in general due to the recruitment of patients via the internet. However, we tried 
to limit this effect by enabling participants to fill out the questionnaires on paper. 
A minimum follow up of 6 months was chosen for pragmatic reasons to allow 
for sufficient statistical power. The median follow-up duration was 103 weeks, 
indicating that 50% of the study population had a follow up of two years or longer. 
In addition, one third had a follow up between one and two years, and 11% of 
subjects had a follow up of 6-12 months.
Although we previously described the LUMINA population as a clinical based 
cohort, we now feel that it is better to describe it as a ‘well-defined, web-based 
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migraine population’. In our population 70% used triptans. Compared to other 
countries this may seem high but in the Netherlands and some Scandinavian 
countries the use of triptans in population based studies is amongst the highest. 
Furthermore, 87% was previously diagnosed with migraine by a physician, 26% is 
currently seen by a neurologist, 43% by a GP. The remaining 31% is not seen by a 
neurologist or a GP. 
In conclusion, we found a longitudinal association between cutaneous allodynia 
and the number of migraine days. Secondly, we confirmed the association 
between allodynia and depression in the largest well-defined sample of migraine 
patients so far. In clinical practice, awareness that patients with migraine are at 
increased risk of chronification, especially when they suffer from a high migraine 
frequency, allodynia, medication overuse and depression is warranted. Future 
research should further elucidate these relationships and focus on prevention of 
allodynia, thereby protecting migraine patients from chronification. 
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Tables
Table 1. Baseline characteristics of migraine patients who suffer from allodynia 
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Values are the absolute numbers with corresponding % or means ± SD. P-values 
depicted in bold indicate significant differences (p<0.05), using independent-samples 
t-tests and x2 tests appropriately. 
BMI: Body Mass Index
*Migraine attack frequency and number of migraine days per year were self-reported 
estimates. Few (n=21) patients reported more than one attack on one day, probably 
because migraine recurrences were counted as new attacks.
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Table 2: Logistic associations between allodynia and possible determinants in 2331 
participants with migraine.
Odds Ratio 95% CI p
Gender (F vs. M)
Age (years)
BMI (kg/m2)
Age at onset migraine (years)
Migraine subtype (MA vs. MO)
Prophylactics (yes vs. no)
Migraine duration *
Migraine frequency (attacks per year)
 3-6 vs. 1-2
 7-12 vs. 1-2
 13-54 vs. 1-2
 more than 54 vs. 1-2





































Data are odds ratios (multivariate, adjusted for all mentioned covariates) with 95% 
confidence intervals and p-values. Values depicted in bold indicate significant findings. 
For further description of adjustments, see methods. Interaction terms migraine 
frequency*prophylactics and lifetime depression*gender were not significant; the final 
analyses were run without interaction terms. In the baseline measurement the number 
of migraine attacks was measured.
F: Female; M: Male; BMI: Body Mass Index; MO: Migraine without aura; MA: Migraine 
with aura
* Migraine duration was added in a different model, substituting ‘age at onset’
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Data are log transformed regression coefficients (exp(B)) with 95% confidence 
intervals, standardized regression coefficients (Beta) and p-values. Values depicted in 
bold indicate significant findings. For further description of adjustments, see Methods. 
For the follow-up measurement the number of migraine days was measured.
BMI: Body Mass Index; MO: Migraine without aura; MA: Migraine with aura
*Migraine duration was added in a different model, substituting ‘age at onset’
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Table 4: Linear associations between baseline characteristics and the difference in 




95% CI Beta p
Allodynia (yes vs. no)
Gender (F vs. M)
Age (years)
BMI (kg/m2)
Age at onset (years)
Migraine duration *
Migraine diagnosis (MO vs. 
MA)
Prophylactics (yes vs. no)
Baseline number of migraine 
days
 3-6 vs. 1-2 per year
 7-12 vs. 1-2 per year
 13-54 vs. 1-2 per year
 > 54 vs. 1-2 per year































































Data are regression coefficients (B) with 95% confidence intervals, standardized 
regression coefficients (Beta) and p-values. Values depicted in bold indicate significant 
findings. For further description of adjustments, see Methods. Interaction terms 
allodynia*prophylactics and allodynia*depression were not significant. Final analyses 
were run without interaction terms. For the follow-up measurement the number of 
migraine days was measured.
BMI: Body Mass Index; MO: Migraine without aura; MA: Migraine with aura
*Migraine duration was added in a different model, substituting ‘age at onset’
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Figures










Missing variables for primary 
analysis
n=361
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n = 2,692 (88.9%)
Follow-up data available
n = 2,351 (77.6%)
Follow-up time > 6 months
n = 2,081 (68.7%)
All variables for secondary analysis 
available







Follow-up time < 6 months
n = 270
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Abstract 
Objectives 
The aim of this study was to determine the prevalence of depression and 
determinants associated with depression  in a large population of Hemiplegic 
Migraine (HM) patients.
Methods 
We conducted a cross-sectional, validated questionnaire study among 89 well-
defined HM patients and 235 headache-free controls. The prevalence of lifetime 
depression, and its relation to migraine characteristics was assessed.
Results 
HM patients had increased odds for lifetime depression (OR 3.73, 95% CI 2.18-
6.38) compared with controls. Use of acute anti-migraine medication was 
associated with lifetime depression.
Conclusion
Depression is part of the monogenic hemiplegic migraine phenotype. Further 
studies are needed to elucidate the pathophysiological role of HM genes in 
comorbid depression. For now, clinicians should take comorbid depression into 
consideration when starting prophylactic treatment of HM.
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Introduction 
Hemiplegic Migraine (HM) is a rare autosomal dominantly inherited migraine 
subtype, characterized by motor weakness during the aura phase. (1) Three 
genes (CACNA1A, ATP1A2 and SCN1A) have so far been associated with HM. 
Involvement of a fourth gene (PRRT2) in HM has been proposed, but further 
evidence is needed to support this claim. (2) HM is divided into two subtypes: 
Familial Hemiplegic Migraine (FHM), in which at least one first or second degree 
relative has HM, and Sporadic Hemiplegic Migraine (SHM), in which no first or 
second degree relative is affected. 
The relationship between the common types of migraine and depression has 
been thoroughly investigated to identify shared aetiological factors. Bidirectional 
associations have been proven, suggesting shared genetic risk factors. (3, 4) As 
a monogenic migraine subtype, HM constitutes a more homogeneous model to 
study migraine pathophysiology than migraine subtypes with a complex genetic 
background (such as migraine with and without aura). In HM, prevalence of 
depression has only been studied on a very small scale. (5) It has been hypothesized 
that the core pathophysiological mechanisms are similar for HM and other types 
of migraine, with HM representing the severe end of the phenotypic migraine 
spectrum. If there is a direct relationship between migraine and depression, 
one could hypothesize that HM, as a more severe migraine phenotype, may 
be associated with at least an equal prevalence of depression compared to 
patients with common migraine subtypes. Even more, an increased prevalence of 
depression in HM may suggest an involvement of ion channels that are mutated in 
HM in the pathophysiology of (certain subtypes of) depression. 
In this study, we studied the prevalence of lifetime depression in HM and the 




HM patients of Dutch origin were recruited from the HM research database of the 
Leiden University Medical Center including patients who visited our outpatient 
headache clinic or were interviewed by an experienced research-physician (NP) or 
neurologist (GMT). Patients were ineligible to participate, when aged <18 years, or 
when unable to fill in the questionnaires (e.g. due to mental retardation or cognitive 
decline). Healthy individuals willing to participate had to pass a screening and 
additional questionnaire online via the research website of the Leiden University 
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Migraine Neuro-Analysis program (LUMINA). (6) If participants did not report 
any symptoms of migraine, cluster headache, chronic tension type headache or 
medication overuse headache, they were considered  as ‘non-headache’ healthy 
controls. These healthy controls were also sent web-based questionnaires on 
symptoms of (lifetime) depression and demographic characteristics identical to 
the questionnaires that were sent to the HM patients.
Standard Protocol Approvals, Registrations, and Patient Consents 
 
The study was approved by the medical ethics committee of Leiden University 
Medical Center and all participants provided informed consent.
Measurements
Symptoms of depression were determined using validated cut-off scores for the 
Hospital Anxiety and Depression Scale (HADS) and the Center for Epidemiological 
Studies Depression Scale (CES-D). (7, 8) The HADS questionnaire is been used 
in clinical studies as it intrinsically corrects for the overlap between symptoms of 
somatic diseases and depression (e.g. lack of sleep, changes in appetite). Lifetime 
depression was defined as HADS-D ≥8, or CES-D ≥16, or a (past) depression 
diagnosed by a physician or (past) use of antidepressants for depression. The 
combination of current depression questionnaires and lifetime depression 
questions allowed for analyses on both lifetime and current depression. Current 
depression was defined as HADS-D ≥8, and current anxiety was defined as HADS-A 
≥8. Information about headache frequency and anti-migraine medication use was 
collected via an additional questionnaire. Healthy controls were sent the same 
depression questionnaires as the HM patients.
 
Data analysis
General characteristics were reported as medians (and interquartile range) or 
percentages. To take into account that some of the HM patients were family-
related (originating from 18 separate families) we used a Generalized Estimating 
Equations (GEE) regression which can correct for this confounding. GEE was 
applied to study the prevalence of depression corrected for sex, age and the 
presence of related individuals. GEE regression was also used in the analysis of 
determinants associated with depression in HM patients. A p-value of <0.05 was 
considered statistically significant. All analyses were performed with SPSS 20.0 
(SPSS inc., IBM, USA).
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Results
Study population
We included 89 participants with HM and 235 healthy controls in the study (figure 
1). From 132 HM participants in the database, 20 were ineligible because of 
previously stated unwillingness to participate in further research (n=1) or outdated 
contact information (n=19), and 23 decided not to participate (19 familial HM, 4 
sporadic HM). No differences were observed between participants (n=89) and 
non-participants (n=43) in age or sex. Differences in headache frequency and 
medication use between participants and non-participants could not be tested 
because of missing data in the non-participants. Information on genetic status was 
missing for three patients, and in ten patients genetic screening was incomplete.
Comparing HM patients with controls
The prevalence of lifetime depression was 51.7% in HM patients compared to 
21.3% in controls (table 1). In multivariate analysis, with correction for sex and for 
the fact that multiple participants belonged to shared families, a strong association 
with lifetime depression was established (table 2). 
Comparing HM patients with and without lifetime depression
HM patients affected by lifetime depression did not differ from patients without 
lifetime depression in sex, age, HM type, or mutation status (table 3). Migraine 
attack frequency tended to be higher in the depression group. Use of acute anti-
migraine medication (also when analysed separately for analgesics and triptans) 
was increased in patients with depression. Lastly, current anxiety appeared highly 
comorbid with depression.
Discussion
Here we studied the prevalence of life time depression in hemiplegic migraine 
(HM), a rare monogenic subtype of migraine. We found, like in the common types 
of migraine, a four time increased odds compared with controls.
In a previous study, using the same methodology and questionnaires to diagnose 
depression, we found a comparable prevalence of 45% for lifetime depression 
in the common types of migraine. (9) Migraine attacks with typical aura (without 
weakness) frequently occur in HM patients. (10) Therefore, the comorbidity of HM 
with depression could, at least partly, be due to presence of common types of 
migraine in our HM patients. Unfortunately, elaborate migraine characteristics 
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were not included in the questionnaires used in this study. It would, however, have 
been difficult to exclude common types of migraine, as the included HM patients 
may still develop such attacks. We therefore cannot provide exact figures on the 
prevalence of the common types of migraine in our population. 
Depression in common migraine is strongly associated with migraine attack 
frequency and is a risk factor for chronification. (9) Due to the small number of HM 
patients we could not show an association with attack frequency. However, use of 
acute anti-migraine medication (simple analgesics and triptans) was associated 
with depression. Considering increased use of acute anti-migraine medication as 
a proxy for migraine severity, the association may not be dependent on attack 
frequency, but on the severity of accompanying migraine symptoms.
The lifetime prevalence of depression of 21% in the control population 
corresponds to published prevalence rates for depression (11), indicating that 
our measurement of lifetime depression appears accurate. HM patients showed 
increased anxiety which might have contributed to the increased comorbid 
prevalence of depression. Unravelling the exact role of anxiety should be a topic 
for future research. A possible limitation of the study is the fact that some of the 
patients are related to other individuals in the study, because HM families were 
included. However, it turned out that many different families participated, but 
each only contributed a few individuals (supplementary table 1). Furthermore, we 
performed a Generalized Estimating Equations analysis to correct for this possible 
bias. It should be noted that we did multiple statistical tests but kept the level of 
significance at 0.05, as is consistent with an exploratory study. 
Although recent molecular genetic advances have provided insights into 
pathophysiological mechanisms of inherited channelopathies such as HM so 
far no relationship with depression have been shown or investigated. Extensive 
biophysical characterisation in representative model systems will be required to 
determine the contribution of different ion channel variants to the common types 
of migraine in general and the comorbidity with depression. (12) 
Because of the cross-sectional design of our study, we can only speculate on 
the mechanism of action of the comorbidity between HM and depression. Our 
results may indicate that the genes involved in HM may, directly or indirectly, make 
patients more susceptible to depression. It would be interesting to study the role 
of ion channels encoded by CACNA1A, ATP1A2 and SCN1A in large cohorts with 
comorbid depression and common forms of migraine. The high prevalence of 
depression in our HM cohort also may have clinical implications. HM patients 
should be screened for depression, and migraine prophylactics such as flunarizine 
or topiramate which may provoke depressive symptoms should perhaps be 
prescribed with caution in HM patients with active depression. (13) 
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Depression is part of the monogenic hemiplegic migraine phenotype. This 
increased risk of depression in HM patients should receive more attention 
in clinical practice, especially with regard to the choice of prophylactic anti-
migraine medication. In addition, further studies are needed to elucidate the 
pathophysiological role of HM genes in comorbid migraine and depression. 
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Figures and tables
Table 1. Sociodemographic and clinical characteristics. Comparison of of HM 
participants and controls.
HM participants n=89 Controls n=235
Female sex (n (%)) 66 (74.2) 138 (58.7)
Median age in years (IQR) 
(range) 
46 (24) (20-70) 48 (24) (19-77)
HM type FHM (n (%)) 65 (73.0) -
HADS-A median (IQR) (range) 5 (6) (0-17) 3 (3) (0-17)
HADS-D median (IQR) (range) 4 (5) (0-12) 2 (3) (0-16)
CES-D median (IQR) (range) 11 (15) (0-55) 4 (7) (0-41)
Lifetime depression present 
(n (%))
46 (51.7) 50 (21.3)
Current depression present 
(n (%))
36 (40.4) 29 (12.3)
Current anxiety present (n (%)) 32 (36.0) 24 (10.2)
Current depression: HADS-D ≥8. Current anxiety: HADS-A ≥8.
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Table 2: GEE regression with odds of lifetime depression1
Univariate 
OR
95% CI P value Multivariate 
OR
95% CI P value
Presence of HM 4.04 2.38-6.88 <0.001 3.73 2.18-6.38 <0.001
Sex 
( female v. male) 2.18 1.28-3.70 0.004 1.90 1.09-3.30 0.023
Age 0.99 0.97-1.01 0.19 - - -
1 Corrected for multiple individuals from the same family.
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HM type FHM: number of patients that were familial HM cases (and not sporadic). 
R, reference category in GEE. 1 Corrected for multiple individuals from the same family. 2 
without lifetime depression n=39 and lifetime depression n= 42 (due to missing data). 3 
questions specifically stated analgesics for severe headache. 4 no life time depression 
group n=39 and lifetime depression group n= 37 (due to missing data). 5 GEE regression 
performed with category 13-54 attacks per year and > 54 per year merged because of 
small numbers. The Fisher’s exact test using all categories gave a p value of 0.13. 
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Abstract
Objective
A strong association has been established between migraine and depression. 
However, this is the first study to differentiate in a large sample of migraine patients 
for symptom dimensions of the affective disorder spectrum. 
Methods
Migraine patients (n = 3174) from the LUMINA (Leiden University Medical Centre 
Migraine Neuro-analysis Program) study and patients with current psychopathology 
(n = 1129), past psychopathology (n = 477), and healthy controls (n = 561) from 
the NESDA (Netherlands Study of Depression and Anxiety) study, were compared 
for three symptom dimensions of depression and anxiety. The dimensions —lack 
of positive affect (depression specific); negative affect (nonspecific); and somatic 
arousal (anxiety specific)— were assessed by a shortened adaptation of the Mood 
and Anxiety Symptom Questionnaire (MASQ-D30). Within the migraine group, 
the association with migraine specific determinants was established.  Multivariate 
regression analyses were conducted.
Results
Migraine patients differed significantly (p<0.001) from healthy controls for all 
three dimensions: Cohen’s d effect sizes were 0.37 for lack of positive affect, 0.68 
for negative affect, and 0.75 for somatic arousal. For the lack of positive affect and 
negative affect dimensions, migraine patients were predominantly similar to the 
past psychopathology group. For the somatic arousal dimension, migraine patients 
scores were more comparable with the current psychopathology group. Migraine 
specific determinants for high scores on all dimensions were high frequency of 
attacks and cutaneous allodynia  during attacks.
Conclusion
This study shows that affective symptoms in migraine patients are especially 
associated with the somatic arousal component.       
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Introduction
Migraine and depression are both rated among the top 20 of most disabling 
disorders by the World Health Organisation. (1) Previous studies showed that 
persons with migraine have a fivefold higher risk of first-onset major depression 
than persons without migraine. In addition, persons with a lifetime depressive 
disorder have a threefold higher risk of first-onset migraine than persons without 
a depression diagnosis. (2, 3) This bidirectional association suggests a shared 
aetiology, which is supported by several studies indicating shared genetic factors 
in migraine and depression. (4, 5) Besides depression, there is an association 
between anxiety disorders and migraine as well. (6) The economic impact of 
migraine is significantly compounded in patients with comorbid psychiatric 
conditions. (7) Understanding the mechanisms underlying the comorbidity is 
important in order to gain more insight into the mechanism of both migraine and 
depression/anxiety and to develop specific preventive treatments. 
Previous studies in migraine defined depression using either categorical DSM-
IV (Diagnostic and Statistical Manual of Mental Disorders) diagnoses or self-
reported questionnaires. However, although DSM-IV categories are of great use 
in clinical practice, they have arbitrary boundaries, and show much overlap and 
comorbidity. Moreover, high heterogeneity of symptoms and severity within 
one diagnostic category is possible. (8) Depression and anxiety severity scales 
based on self-reported questionnaires also have limitations: two similar scores 
may indicate different clinical subtypes due to the heterogeneity of the covered 
range of symptoms as multidimensionality of symptomatology is not taken into 
account. Consequently, measuring affective disorders with these tools may 
provide suboptimal phenotyping for clinical and biological (e.g. genetic) research. 
Thus, in a research setting, it may be more appropriate to study dimensions of 
depressive and anxiety symptoms in migraine patients as these seem to reflect 
more homogeneous disease entities. 
Several attempts have been made to develop a dimensional model for depression. 
Within a dimensional approach, a patient is described in terms of scores on a 
range of coexisting different symptom domains, and not in terms of presence 
or absence of psychopathology. (9) A well-known model is the tripartite model 
that accounts for the overlap between depression and anxiety. (10) In this model 
the broad symptom dimension of negative affect covers symptoms of general 
psychological distress (e.g. lack of concentration or pessimism). High negative 
affect has often been indicated as a central clinical feature of both anxiety 
and depression, accounting for the high rates of comorbidity. (11-14) The lack 
of positive affect covers anhedonic symptoms, which are mainly specific for 
depression. The somatic arousal dimension comprises symptoms of hyperarousal 
which are anxiety specific.
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The aim of the present study is to investigate whether migraine patients 
are characterized by different symptom patterns of depressive and anxiety 
symptomatology compared with healthy controls, and persons with a current 
or past depression and/or anxiety disorder. Furthermore, we investigate which 
migraine specific characteristics are associated with the affective symptom 
dimensions of the tripartite model.
Methods
Study design and population
Four groups were differentiated for comparison: i) migraine patients, ii) healthy 
controls without psychopathology and without migraine, iii) persons with ‘current 
psychopathology’, a 6-month diagnosis of major depressive disorder, dysthymia or 
anxiety disorder and without migraine, and iv) persons with ‘past psychopathology’, 
a lifetime (but no current) diagnosis of major depressive disorder, dysthymia or 
anxiety disorder and without migraine.
Migraine patients were collected as a part of the Leiden University Medical Centre 
Migraine Neuro-analysis Programme (LUMINA) project, a well-defined web-
based migraine population, the details of which are reported elsewhere. (15) The 
LUMINA project is an ongoing cohort study, designed to investigate migraine, 
its comorbidities, and its long-term course.  Participants were Dutch adults aged 
18 to 74 years with migraine with or without aura according to the International 
Classification of Headache Disorders (ICHD-III beta) criteria. (16) The LUMINA 
study population recruitment is still ongoing, but we included participants 
recruited between 2008 and 2011. Participants were recruited via nationwide 
public announcement, advertising in lay press and via the research website, 
inviting migraine patients to participate in migraine research (see supplementary). 
In addition, patients attending our dedicated headache clinic were also invited 
to participate in this survey. This latter group, however, comprises only 3.5% of 
the total LUMINA population. On the website, patients were asked to fill out a 
screening questionnaire that has been validated priorly. (17) Firstly, if patients 
fulfilled the screening criteria, they received a web-based extended migraine 
questionnaire, based on the ICHD-III beta criteria. (15, 16) This questionnaire was 
previously validated by a semi-structured telephone interview in 1038 patients 
who had filled out the extended migraine questionnaire. (15) The specificity of 
the questionnaire was 0.95. Participants without the needed internet skills could 
fill out the questionnaires on paper. Secondly, all applicable migraine patients 
were selected for a web-based questionnaire on symptoms of affective disorders. 
Patients were enrolled in this study after completion of the affective disorders 
questionnaire. The response rate to the depression questionnaire was 80%.
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Healthy controls and patients with psychopathology were derived from the 
Netherlands Study of Depression and Anxiety (NESDA), which is an ongoing 
cohort study designed to investigate the long-term course and consequences of 
depressive and anxiety disorders. Participants were adults aged 18-65 recruited 
from community (19%), general practice (54%), and secondary mental health 
(27%) facilities. A total of 2981 participants, including persons with current or 
past depressive and/or anxiety disorders and healthy controls, were assessed at 
baseline between 2004 and 2007. Exclusion criteria for the NESDA study were 
inability to speak Dutch and a known clinical diagnosis of other psychiatric 
conditions, such as bipolar disorder, obsessive-compulsive disorder, severe 
addiction disorder, psychotic disorder or organic psychiatric disorder. A detailed 
description of the NESDA study design can be found elsewhere. (18) In summary, 
the baseline assessment was comprised of a face-to-face interview, including a 
standardized diagnostic psychiatric interview, a medical assessment, computer 
tasks, written questionnaires, and biological measurement. For the current study, 
migraine patients, identified through a screening migraine questionnaire largely 
in accordance to the ICHD-III beta criteria for migraine (described in detail 
elsewhere), were excluded from the NESDA population. (19)
The LUMINA project was approved by the medical ethics committee of the Leiden 
University Medical Centre. The NESDA research protocol was approved by the 
Ethical Committee of participating universities. All respondents provided written 
informed consent.
Measurements
In the NESDA study, the presence of psychiatric disorders was determined by 
using the Composite International Diagnostic Interview (CIDI, version 2.1). The 
CIDI is a standardized psychiatric diagnostic interview that follows the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria to 
establish diagnoses. The CIDI is a highly reliable and valid instrument for assessing 
depressive and anxiety disorders and was administered by specially trained 
research staff. (20) Psychopathology (major depressive disorder, dysthymia, anxiety 
disorder) status was categorized as follows: current diagnosis (i.e., past 6 months), 
past diagnosis (i.e., lifetime diagnosis but not in the past 6 months), controls (no 
lifetime diagnosis). In both the LUMINA and NESDA studies, a 30-item adaptation 
of the Mood and Anxiety Symptoms Questionnaire (MASQ-D30) was used to 
measure the tripartite dimensions of depression. On the MASQ-D30, participants 
were asked to rate to what extent in the past week they had experienced ‘feelings, 
sensations, problems and experiences that people sometimes have’ on a 5-point 
scale, with 1 being ‘not at all’ and 5 being ‘extremely’. 
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The three 10-item subscales are ‘general distress’ (lack of positive affect), 
‘anhedonic depression’ (negative affect) and ‘anxious arousal’ (somatic arousal). 
The MASQ-D30 scales showed adequate psychometric characteristics and 
showed good reliability and validity within the NESDA study. (21) 
In the LUMINA population, we predefined migraine specific characteristics to be 
examined: migraine subtype (migraine with or without aura), frequency (migraine 
days per year), and cutaneous allodynia. Cutaneous allodynia, the perception of 
pain in response to non-noxious stimuli to the normal skin, is a common feature 
accompanying migraine attacks. A significant part of migraine patients experience 
an increased sensitivity of the skin for common daily activities during attacks, 
such as combing of hair, taking a shower, touching the periorbital skin, shaving, 
or wearing earrings during migraine attacks. Cutaneous allodynia was measured 
using a validated questionnaire. (22) These migraine specific characteristics are 
shown to be associated with depression. (23, 24) 
Data analysis and statistics
Baseline characteristics were reported as mean ± standard deviations (SD) 
or percentages. Analysis of covariance (ANCOVA) models were used to test 
the association between the four different groups and MASQ-D30 symptom 
profiles, adjusting for gender and age. Post-hoc analyses were run in case of 
significant findings, performing ANCOVA analysis to test for differences between 
the migraine group and the three remaining groups. Results were presented 
as p-values with Cohen’s d (the difference between the means, divided by the 
pooled standard deviation) as a measure of effect size. Secondary analyses were 
performed in the migraine population, using multivariate linear regression, testing 
for the association between general and migraine specific determinants and the 
three dimensions of affective disorders. Results were presented as p-values and 
B-values with 95% confidence intervals. For the primary analyses, we measured 
three outcomes (the three subscales of the MASQ-D30 questionnaire). Therefore, 
using Bonferoni correction for multiple testing,  p-values <0.017 (0.05/3) were 
considered as statistically significant. Secondary, hypothesis generating analyses, 
were performed without correction for multiple testing. All analyses were 
performed using SPSS 20.0 (SPSS Inc., IBM, USA). 
Results
Of 2981 NESDA participants, 454 fulfilled the criteria for migraine, and 360 
lacked MASQ-D30 data and were excluded for analysis. As a result, the total 
amounts of participants were 1129 with current psychopathology, 477 with past 
psychopathology, and 561 healthy controls. A total of 3174 migraine patients with 
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sufficient data on migraine characteristics and MASQ-D30 data were extracted 
from the LUMINA database. The total study flow is depicted in figure 1. 
Baseline characteristics for the four groups are shown in table 1. Because of 
differences in gender distribution and age distribution between the four groups 
(p < 0.001), all analyses were corrected for gender and age. As the LUMINA and 
NESDA cohorts had different assessments of educational level the analyses were 
not corrected for that socio-demographic characteristic.
In the first analysis (table 2) the four groups (migraine patients, healthy controls, 
persons with past psychopathology, and persons with current psychopathology) 
were compared using a multivariate linear regression analysis with adjustment for 
age and gender. There was a significant difference (p<0.001) between the four 
subgroups for the three symptoms dimensions (lack of positive affect (depression 
specific); negative affect (nonspecific); and somatic arousal (anxiety specific)). 
Further pairwise comparison with migraine as reference group is depicted in figure 
2. Migraine patients were significantly different (p<0.001) for all comparisons to the 
two psychopathology groups and healthy controls, except for the lack of positive 
affect compared with the past psychopathology group. In figure 2, differences 
between the groups are displayed as Cohen’s d, a measure of effect size, showing 
that scores on the lack of positive affect (Cohen’s d=0.07) and negative affect 
(Cohen’s d=0.30) dimensions for migraine patients are most closely related to the 
past psychopathology group. For the somatic arousal subscale scores migraine 
patients are closer related to current psychopathology (Cohen’s d=0.25).
Within the group of migraine patients (n=3174), general and migraine specific 
determinants for the three subscales of affective disorders were analysed using 
multivariate linear regression (table 3). Age was significantly associated with lack 
of positive affect and negative affect. Gender was significantly associated with 
somatic arousal. Migraine frequency and cutaneous allodynia, but not migraine 
subtype, were associated with all three symptom dimensions of the affective 
disorder questionnaire.
Discussion
This is the first study differentiating in a large sample of migraine patients for 
symptom dimensions of depression and anxiety. In comparison with healthy 
controls and persons with past or current psychopathology, affective disorder 
symptoms in migraine are specifically associated with higher scores on the 
dimension somatic arousal which covers symptoms of hyperarousal. Furthermore, 
the association between MASQ-D30 scores and migraine frequency, which can be 
considered as an indication of migraine severity, is the strongest on the somatic 
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arousal subscale. Besides migraine frequency, we show that cutaneous allodynia 
is associated with higher scores on all three symptom dimensions as well. 
Our finding that migraine is particularly associated with the somatic arousal 
dimension is in accordance with that of several other somatic disorders. Association 
studies investigating the relationship of depression with chronic diseases like 
diabetes, obesity, and cardio-vascular disease often show that somatic-affective 
symptoms of depression rather than cognitive-affective symptoms are related to 
somatic disease (25-28). Therefore, it is often hypothesized that the association 
between a somatic disease and depression is primarily through the somatic-
affective dimension of depression, the so-called somatic depression (29, 30). 
One might also argue that part of the comorbidity between migraine and affective 
disorders could be due to overlapping symptomatology. Some of the characteristic 
features of migraine attacks, such as nausea, loss of energy, anhedonia, and sleep 
disturbances, could lead to misclassification of depressive disorder in migraine 
patients. However, the association of migraine and depression is still present when 
questionnaires focusing on the non-somatic aspects of depression are applied, 
such as the Hospital Anxiety and Depression Scale) (24). Furthermore, the current 
study clearly shows that the symptom profile of affective disorders in migraine 
patients differs from healthy controls for all three dimensions of the MASQ-D30 
questionnaire, not only for the somatic arousal dimension.  Therefore, our study 
shows that affective disorders in migraine patients cannot be fully explained 
by somatic depression or overlapping symptomatology. However, our study 
does suggest an even stronger comorbidity between migraine and symptoms 
of anxiety, than between migraine and symptoms of depression per se. This is 
particularly interesting, since most studies hitherto focused on the comorbidity 
between migraine and depression, whilst the comorbidity of migraine and anxiety 
is a largely unexplored area. Larger and prospective studies on the comorbidity 
of migraine and anxiety disorders are necessary to establish the exact magnitude 
of this comorbidity. 
Our study shows that anxiety arousal might be the corresponding component, but 
the underlying mechanism should be further investigated. 
Because the co-occurrence between migraine and affective disorders is not 
fully explained by mechanisms such as somatic depression or overlapping 
symptomatology we argue that there is a true comorbidity between migraine and 
depression. Additionally, previous studies showed a bidirectional relationship, in 
which the risk for depression is five times increased in migraine patients, and vice 
versa, the risk for migraine is three times increased in patients with depression 
(2, 3). This bidirectional association suggests shared underlying mechanisms, 
presumably shared genetic factors (4, 5). However, further genetic research did 
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not yet result in clues which exact genes are involved in this association. The 
current study stresses the importance of a dimensional approach for depression 
in migraine in a research setting, as the current concept of depression probably 
is too heterogeneous for detecting genetic variants involved in this association. 
Using subgroups of migraine patients, based on the tripartite model of depression 
and anxiety, may be warranted in further genetic research on the comorbidity of 
migraine and affective disorders.
Comorbid depression in migraine is an important predictor of substance 
dependence and is common in chronic migraine patients, in particular in those 
with overuse of acute headache medication (31). Thus a triad between migraine 
chronification, depression and medication overuse has been suggested (32-
34). In this triad, cutaneous allodynia plays a role. Allodynia, the perception of 
pain in response to non-noxious stimuli to the normal skin, is a common feature 
accompanying migraine attacks. Previously, we showed that depression and 
high migraine attack frequency (as a marker of chronification) are independently 
associated with cutaneous allodynia (23). The present study supports this finding 
and shows that both cutaneous allodynia and high migraine frequency, are 
associated with all three symptom dimensions of affective disorders, covering 
general distress as well as anxiety and depression specific symptoms.
The strengths of this study are the large sample size, the well-defined migraine 
status in the LUMINA population, the well-defined psychopathology status in 
the NESDA population, and the well-defined healthy control population from 
NESDA. Most importantly, this is the first study focusing on the different symptom 
dimensions of affective disorders in migraine patients. Possible limitations include 
the fact that we compare two different cohorts, in which data was collected in 
different ways and time periods. 
In conclusion, we found that migraine patients, without taking their history of 
psychopathology into account, differ significantly from healthy controls on all three 
dimensions of affective disorders. The strongest difference is seen on the somatic-
affective component which is suggestive of increased anxiety. Using subgroups 
of migraine patients, based on the tripartite model of affective disorders, may be 
warranted in further biological research on the comorbidity of migraine, anxiety 
and depression.
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Figures and tables
Figure 1: Study flow
LUMINA = Leiden University Medical Centre Migraine Neuro-analysis Program
NESDA = Netherlands Study of Depression and Anxiety
MASQ-D30 = Mood and Anxiety Symptoms Questionnaire
NESDA population                    
N = 2981
LUMINA population                    
N = 3174 
Migraine  
N = 3174
Reason for exclusion: 
Migraine (N=454) 
Missing MASQ-D30 data (N=360)
NESDA population      
N = 2167 
Current 
psychopathology
 N = 1129
Past 
psychopathology
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MASQ-NA = negative affect subscale
MASQ-SA = somatic arousal subscale
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           Figure 2: effect sizes of the difference between migraine patients compared with 
          healthy controls, past psychopathology and current psychopathology.
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Abstract
Aim 
To determine whether support of a headache nurse in the treatment of Medication 
Overuse Headache (MOH) increases successful withdrawal, and to study 
determinants of response to withdrawal therapy. 
Methods 
A retrospective controlled follow-up study was performed with 416 MOH patients. 
All patients were treated with outpatient withdrawal therapy, with two treatment 
arms: with or without the support of a specialized headache nurse. The outcome 
measures were: i) successful withdrawal, defined as discontinuation of all headache 
medication according to the study protocol; and ii) the responder rate, defined as 
the percentage of patients with ≥ 50% reduction in headache days after successful 
withdrawal and iii) relative reduction in headache days after successful withdrawal. 
Results 
Successful withdrawal percentages were significantly higher in the group 
supported by the headache nurse than in the group without support (73.1% vs. 
60.7%; p=0.008), which was confirmed in multivariate analysis (OR 1.73, 95% 
CI 1.11-2.71, p=0.016). Support by a headache nurse was not associated with 
response. The underlying headache primary headache diagnosis, determined 
after withdrawal, was significantly correlated with response. 
Conclusion 
The support by a headache nurse results in an increased adherence to 
detoxification. 
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Introduction 
Medication Overuse Headache (MOH) is a highly disabling headache disorder, 
with a population based prevalence of 0.7 - 1.7% and a preponderance in women. 
(1-3) The prevalence in headache clinics ranges from 30% in Europe to more than 
50% in the USA. (1, 2)  MOH is defined in the ICHD-III-beta criteria as headache 
occurring on half or more days per month as a consequence of regular overuse of 
acute headache medication (on ≥10 or ≥15 days per month, depending on the type 
of medication) for more than 3 months. (4) Although consensus about the optimal 
treatment for MOH is not yet reached, withdrawal of the overused medication 
is strongly suggested as an essential component in the management of MOH, 
to reduce headache frequency and improve responsiveness to both acute and 
prophylactic therapy. (1, 2, 5, 6) Several studies have compared different treatment 
strategies and some suggested that a simple withdrawal advice is effective. (2, 
7-9) In compliance with those studies, acute withdrawal without any concomitant 
therapy is advised in the national headache guidelines of the Netherlands, and 
common practice. However, a well-defined selection of patients prone to benefit 
from simple withdrawal advice has not been established. Withdrawal programmes 
are increasingly multidisciplinary coordinated, with implementation of patient 
education and motivational or cognitive behavioural therapy, often realized by 
a headache nurse. (10-14) Despite of this, the effectiveness of a headache nurse 
in withdrawal therapy has never been studied in a controlled follow up study. 
Therefore, the objectives of this study are (i) to determine whether support of a 
headache nurse in the treatment of MOH increases successful withdrawal, and 
(ii) to investigate intrinsic patient factors associated with response to withdrawal 
therapy. 
Methods 
Study design and population 
The current study used a retrospective controlled follow-up approach. Participants 
were recruited during a period of four years (1 April 2006 - 31 March 2010) 
among all new patients at the specialized outpatient headache clinic of the Leiden 
University Medical Centre (LUMC), functioning both as a primary and secondary 
referral centre with referrals from general practitioners and from colleague 
neurologists. Inclusion criteria for participants were: (i) age ≥ 18 years; (ii) diagnosis 
of MOH, defined by the ICHD-II criteria, which are similar to the ICHD-III-b criteria 
on MOH (supervised by an experienced headache neurologist (MDF, GMT)); 
and (iii) receiving an advice to withdraw all acute headache medication (triptans, 
analgesics, combination of both, other medication comprising opioids, ergots 
or combinations of those medications with analgesics or triptans), prophylactic 
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medication and caffeine (-containing liquids) during two or three months. (4, 
15) Follow up occurred after withdrawal, to determine the final underlying 
primary headache diagnosis and start further treatment. At the first visit patients 
were instructed that because of lack of therapeutic options whilst overusing 
medication, no follow-up visit was offered if they did not succeed to withdraw. 
Therefore, patients who were lost to follow-up were considered as ‘not successfully 
withdrawn’. Patients were excluded when the final diagnosis was not migraine, 
tension-type headache or a combination of both. The treatment protocol for 
patients included between 1 April 2006 and 31 March 2008 (group A) comprised a 
withdrawal advice by a resident-in-neurology/neurologist. All physicians involved 
during the total inclusion period, gave the same instructions and maintained the 
same conditions of withdrawal, according to the standardised protocol at the 
LUMC. This encompassed an outpatient detoxification with the advice to instantly 
stop acute headache medication. The duration of the withdrawal period was two 
months in case of triptan overuse, three months for other types of medication or 
combinations of medication, and/or caffeine use of ≥ 5 units/day. If patients were 
on preventive treatment this was tapered off, since the present medication was 
not effective, and preventive medication regains effectiveness after withdrawal. 
(6) New preventive treatment was postponed until successful withdrawal was 
accomplished. Use of escape medication or caffeine (-containing liquids) was not 
permitted. During the withdrawal period no facility was provided for additional 
contacts or support. Due to the employment of specialized headache nurse ever 
since 1 April 2008, patients included between 1 April 2008 and 31 March 2010 
(group B), were advised exactly the same withdrawal protocol, but additionally 
received support during the withdrawal period by a specialized headache nurse. 
The headache nurse was trained and experienced in headache care, and received 
additional training on cognitive behavioural therapy. The support by the headache 
nurse started immediately during the first visit with a 15-30 minutes consultation 
consisting of a reprise of the withdrawal advice and elaboration on questions of the 
patient. The consequences for daily professional and social life were discussed and 
a plan of approach was assembled. Furthermore, strategies for pain management 
(other than medication treatment) were discussed. Subsequently, the headache 
nurse contacted all patients two weeks after initiation of the withdrawal period. 
Depending on the need for support of patients, the headache nurse had additional 
interaction during the withdrawal period, varying from one to six contacts (median 
three contacts) by telephone. 
Measurement 
Two trained examiners obtained medical information from the outpatient clinic 
administration, patient letters and medical files, using the same methods and 
criteria to select patients and classify data. The outcome measures were: i) 
successful withdrawal, defined as a completed medication- and caffeine- free 
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period; ii) response, defined as ≥ 50% reduction in headache days after successful 
withdrawal; and iii) relative reduction in headache days after successful withdrawal, 
since a reduction <50% may be considered clinically relevant as well. (16) The 
number of headache days at baseline and at follow up were collected to calculate 
outcomes measures. In case of missing data on response (n=24 patients), patients 
reporting ‘strong improvement’, ‘nearly no headache’ or ‘no headache’ at follow-up 
were considered as a ≥ 50% reduction in headache days(responder), and patients 
reporting ‘aggravation’, ‘no improvement’ or ‘some to moderate improvement’ 
at follow-up were considered as a < 50% reduction in headache days (non-
responder). This subjective classification and the classification based on absolute 
change in headache days were highly correlated (n=75, r = 0.80, p<0.001). To 
be able to find associations between potential intrinsic determinants and our 
outcome measures, we collected data on gender, age, pre-existing headache type, 
final primary headache after successful withdrawal, number of headache days at 
baseline, number of medication days at baseline, type of overused medication, 
and caffeine units per day. Pre-existing headache and final primary headache at 
follow-up were classified according to ICHD-II/ICHD-III-b criteria as: i) migraine; 
ii) tension-type headache; and iii) combination of both migraine and tension-type 
headache. (4, 15) Because of the typical blurred presentation of primary headache 
at baseline, which is often the case during a period of medication overuse, the pre-
existing headache was in some cases impossible to determine (n=85). Therefore, 
final primary headache diagnosis was used in the analysis. In any case, pre-existing 
and final headache diagnoses were fairly correlated (n=182, r=0.62, p<0.001). 
Type of acute medication was classified as: i) triptans, ii) analgesics (paracetamol/
acetaminophen and/or NSAIDs), iii) combination of triptans and analgesics, 
and iv) other medication, comprising opioids, ergots or combinations of those 
medications with analgesics or triptans. No approval of the local ethics committee 
was necessary as the study was a retrospective follow-up study and all data were 
analysed anonymously.
Data analysis and statistics 
Baseline characteristics were reported as mean ± SD or absolute numbers with 
percentages. The number of headache days and medication days at baseline were 
grouped into daily (30.4 days/month) and non-daily (<30.4 days/month), because 
of the non-parametric distribution of the data. Differences in means between 
groups were tested with independent samples t-tests and one-way ANOVAs. 
Differences in proportions were tested using x² tests. Patients were stratified into 
‘successfully withdrawn’ and ‘not successfully withdrawn’, the latter including 
patient who were lost to follow-up. All patients were included in the analysis of 
the first outcome (successful withdrawal). Successfully withdrawn patients were 
included in the analysis of the second and third outcomes (response respectively 
relative reduction). Univariate logistic regression models were used to test crude 
104 | Chapter 6
associations. Analyses were rerun as a multivariate model, adjusting for the 
potential confounding effects of all variables that were tested in the univariate 
model. For all analyses, two-tailed p-values < 0.05 were considered as statistically 




The total study flow is shown in Figure 1. Of 2086 new outpatients, 416 patients were 
diagnosed with MOH and advised to withdraw medication, 163 without (group 
A) and 253 with support of a headache nurse (group B). Both groups differed 
significantly in gender, age, type of medication and daily use of medication (Table 
1). Although the absolute number of new headache patients visiting the outpatient 
headache clinic raised in the last two years of the inclusion period, the proportion 
of patients who met inclusion criteria remained the same (19.0% in group A and 
20.6% in group B). To detect shifts in population composition due to exclusion of 
patients, lost to follow-up or missing data, differences between the total included 
population (n=416) and the population that had successfully withdrawn (n=267) 
were explored. No major differences in composition occurred.  
Effectiveness of support by a headache nurse in successful withdrawal in MOH
As shown in Table 2, the percentage of patients with successful withdrawal was 
significantly higher in the group with support of the headache nurse than the 
group without support (73.1% vs. 60.7%, p = 0.008, Absolute risk reduction = 
12.4%, Number Needed to Treat = 8). As a consequence of the instructions at the 
first visit (not to come for a second visit if withdrawal was not successful) a larger 
proportion of patients of group A did not visit for a second time, and were lost to 
follow up (27.0% vs. 12.3%). However, the results were similar when lost to follow-
up patients were analysed as a separate group. The support by a headache nurse 
was significantly associated with the odds for successful withdrawal in multivariate 
regression (Odds Ratio [OR] 1.73; 95% CI, 1.11 – 2.71; p=0.016)(Table 3), 
indicating that the support by a headache nurse enhances successful withdrawal, 
independent of age, the number of headache days, medication days and type of 
medication overuse at baseline. Daily use of headache medication and a higher 
ager were associated with lower odds for successful withdrawal (OR 0.50; 95% CI 
0.30 – 0.83; p=0.008 resp. OR 0.98; 95% CI 0.96 – 0.99; p=0.017).       
  6
Detoxification in medication veruse headache, a retrospective Controlled | 105 
follow-up study; Does care by a headache nurse lead to cure?
Variables associated with response and relative reduction to withdrawal therapy
The support by a headache nurse was not associated with response (OR: 1.42; 95% 
CI, 0.78–2.60; p=0.25) (Table 4). The responder rate, defined as the percentage 
of patients with ≥50% reduction in headache days, was not significantly different 
in both groups (no support 35.5%, with support 46.0%, p=0.098, Figure 2). The 
relative reduction in headache frequency, also showed no significant association 
with support by a headache nurse (B: 1.92; 95% CI, -7.75–11.60; p=0.70) This 
indicates that there is no effect of the support by the headache nurse on reduction 
of headache days when successfully withdrawn. The underlying primary headache 
disorder, that remained after the withdrawal, was significantly associated with 
relative reduction and response, with a three times increased odds for response 
in case of migraine when compared to tension type headache (OR 0.31, 95% CI 
0.16-0.63; p<0.001), and a nine times increased odds in case of migraine when 
compared to migraine with tension type headache (OR 0.11; 95% CI 0.05-0.24; 
p<0.01)(Table 4). This gives a clear indication that the reduction in headache 
frequency was highest in the migraine group and lowest in the migraine with tension 
type headache group (Table 4, also depicted in Figure 2). The relative reduction 
in headache days, was 34.2% ± 38.9 for the total group and was significantly 
different between persons with migraine, tension type headache, and combined 
migraine and tension type headache (resp. 56.1% ± 32.1, 26.0% ± 39.6 and 16.0% 
± 31.9) (Figure 3). As shown in Table 4, gender and age were not associated with 
response, nor was the number of headache days or number of medication days at 
baseline. Furthermore, neither the type of medication that was overused (simple 
analgesics, triptans, combination of both, or other medication) nor caffeine use 
was associated with response. These covariates were not associated with relative 
reduction as well.  
Discussion 
Being the first controlled follow-up study, this study shows that support of a 
headache nurse during simple withdrawal therapy increases the chance that 
a patient with Medication Overuse Headache (MOH) successfully withdraws 
from overused medication. In this manner, the high drop-out percentage seen 
in outpatient withdrawal therapy can be reduced. (7) As expected, the reduction 
in headache days during withdrawal therapy is independent of the support of a 
headache nurse, as this is more likely to be influenced by intrinsic, patient related 
factors. The current study shows that patients with migraine as the solely underlying 
headache disorder have a higher chance at response to withdrawal therapy. 
The strengths of this study include the controlled design in a large, representative 
study population of MOH patients. Although randomisation was not achievable, 
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the retrospective design is particularly suited to determine the effect of the 
headache nurse, since we studied the insulated effect of the nurse and there were 
no ethical issues or risk of blinding failure. We changed our treatment protocol of 
patients with MOH during our inclusion period by the employment of a headache 
nurse in April 2008, but no other changes regarding to treatment protocol 
or referral strategies were introduced. In a prospective controlled study, the 
recruitment procedure would lead to a highly motivated population, and it would 
be extremely difficult to blind patients for receiving or not receiving support by 
a nurse, since patients must be informed about the nature of a study. One group 
of patients would thus be instructed not to contact the outpatient clinic at any 
moment, whilst they know about the availability of support to the other group. This 
will definitely introduce disappointment and other expectations and will bias the 
results in favour of the intervention. The results of our retrospective study are not 
influenced by this kind of bias. 
There are also some limitations of our study design. Firstly and most importantly, 
there was no ability to collect data of patients who did not return for a second 
visit and were, therefore, stated as lost to follow-up. Since patients were explicitly 
instructed that they were not allowed to revisit in case of unsuccessful withdrawal, 
and they were informed that no additional treatment would be supplied, we 
consider the majority of the lost to follow up patients as unsuccessfully withdrawn. 
We reckon the possibility that lost to follow-up is caused by economic reasons 
negligible due to the health care system in our country, and the visit could be 
changed to a 15-30 minute telephonic appointment in case patients definitely 
could not miss work. Analysis considering lost to follow-up as unsuccessfully 
withdrawn shows similar result as analysis with lost to follow-up patients as a 
separate group. Secondly, for the reason of uncertainty about diagnoses before 
withdrawal, we diagnosed the primary headache disorder only after successful 
withdrawal, and used this diagnosis. Still, the pre-existing primary headache 
diagnosis was fairly correlated with final diagnosis. Thirdly, long-term effects of 
withdrawal were not investigated in this study. Considering the high recidivism 
rate, it would be interesting in future research to study the long term effect of a 
headache nurse in patients with MOH after withdrawal. However, the long term 
effect of a headache nurse on medication overuse was beyond the scope of this 
study as we specifically wanted to investigate the response to the initial withdrawal 
period. In many countries patients with MOH are usually unwilling to endure 
acute withdrawal therapy. Patients in these countries refuse to discontinue their 
medication on the grounds that the withdrawal symptoms will be too serious or 
they are afraid to lose their jobs if they will be ill for a longer period because of the 
withdrawal symptoms. There is usually a drug treatment started with prophylactics 
although it is recognized that it often fails if the patient continues to overuse acute 
headache medication.  Therefore, it was of our main interest to show the high 
success rate of acute withdrawal with the support of a headache nurse.
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In literature, several withdrawal therapies, sometimes with the support by a 
headache nurse for MOH patients have been described, but no other study 
investigated the insulated effect of a headache nurse and uniform endpoints are 
lacking, hampering direct comparison between studies. (11-14, 16)
Possible explanations and implications                
The headache nurse has an unmistakable effect on succeeding withdrawal therapy. 
Previous studies suggest that patients with (chronic) headache or high headache 
related disability, are more prone to use unsuitable coping mechanisms (17), score 
low on pain acceptance (18) and high on catastrophizing scales, and experience 
a low internal pain control. (19) In patients with migraine, pain control and self-
management can be improved by behavioural therapy. (20) We hypothesize that 
contact with a headache nurse influences the above mentioned factors and thus 
will help patients to endure the withdrawal period. Patients with tension-type 
headache and the combination of migraine and tension-type headache seem to 
benefit less from withdrawal therapy than patients with migraine alone, which may 
suggest that the pathophysiological mechanism of medication overuse differs 
between different underlying primary headache syndromes. 
Nowadays the view on treatment of MOH shifts from the traditional ‘withdrawal 
therapy first’ towards an approach in which prophylactic therapies are started 
before patients are withdrawn from the overused medication. Randomised trials 
in chronic migraineurs with topiramate and onabotulinum toxin A, contributed 
significantly to the debate whether, and when, detoxification is necessary in the 
treatment of MOH. (21-24) From these trials the question remains, however, 
whether the effect is clinically relevant. Moreover, the studies lack adequate 
reporting of plausible blinding failure, and most importantly, in these trials 
withdrawal was not advocated. To illustrate, the responder rate of migraineurs 
in our study is comparable to the responder rate in the pooled results of the 
onabotulinum toxin A trials. We realize that in our population not many patients 
overuse barbiturates or opiates, which enables acute medication withdrawal, in 
accordance with our national guidelines. Nevertheless, our study shows that with 
the support of a headache nurse, comprising only one face-to-face contact and a 
median of three contacts by telephone, 75% of MOH patients succeed to undergo 
a highly cost-effective outpatient withdrawal therapy, which is easily implemented 
in general neurology practice. 
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Figures and tables
Table 1: Baseline characteristics of patients with medication overuse headache, 
included for primary analysis, without (group A) and with (group B) support by a 
headache nurse (n = 416). 
A. No headache 
nurse (n=163)
B. Headache nurse 
(n=253) p
Gender, % female
Age at time of diagnosis
Headache days 









































Values are the absolute numbers with corresponding % or means ± SD. Significant p 
values are depicted in bold. 
* x² test  
** two-tailed independent samples t-test  
*** Independent Samples Mann-Whitney U test
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Table 2: Successful medication withdrawal, defined as a 2-3 months medication- and 
caffeine-free period, in patients with MOH following withdrawal therapy without (group 
A) and with (group B) support by a headache nurse (n = 416). 
A. No headache nurse 
(n=163)










MOH = Medication Overuse Headache. Values are the absolute numbers with 
corresponding %. 
* Including patients who are lost to follow-up and therefore considered not successfully 
withdrawn 44 (27.0%) resp. 31 (12.3%). 
** x² test
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Table 3: Odds Ratios (1. univariate; 2. multivariate, adjusted for all mentioned covariates) 
for successful withdrawal, defined as a 2-3 months medication- and caffeine-free 






























1.09 [0.69 – 1.72]
0.98 [0.96 – 0.99]
1.00
1.76 [1.16 – 2.68]
1.00
0.97 [0.64 – 1.48]
1.00 
0.97 [0.44 – 2.16]
0.87 [0.55 – 1.38] 
0.55 [0.25 – 1.20]
0.99 [0.94 – 1.05]
1.00
















0.88 [0.53 – 1.44]
0.98 [0.96 – 0.99]
1.00
1.73 [1.11 – 2.71]
1.00
1.36 [0.82 – 2.25]
1.00
1.22 [0.52 – 2.25]
0.80 [0.50 – 1.30]
0.68 [0.29 – 1.61]
1.00 [0.94 – 1.06]
1.00















* n=409, due to missing data
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Table 4: Odds Ratios (1. univariate; 2. multivariate, adjusted for all mentioned 
covariates) for response, defined as a ≥ 50% reduction in headache days, following 












  No support
  Support
Diagnosis 
  Migraine 
  TTH
  TTH and migraine
Headache days (baseline)
  Non-daily 
  Daily
Medication 
  Analgesics 
  Triptans




  Non-daily 
  Daily
1.00
1.43 [0.82 – 2.49]
1.00 [0.98 – 1.02]
1.00
1.55 [0.92 – 2.60]
1.00
0.26 [0.14 – 0.46]
0.10 [0.05 – 0.22]
1.00
0.47 [0.28 – 0.77]
1.00 
1.00 [0.41 – 2.47]
1.63 [0.95 – 2.78] 
0.52 [0.16 – 1.69]
1.01 [0.94 – 1.08]
1.00



















1.14 [0.59 – 2.18]
1.00 [0.98 – 1.02]
1.00
1.42 [0.78 – 2.60]
1.00
0.31 [0.16 – 0.63]
0.11 [0.05 – 0.24]
1.00
0.84 [0.45 – 1.57]
1.00
0.54 [0.18 – 1.61]
1.24 [0.64 – 2.41]
0.38 [0.11 – 1.33]
1.02 [0.94 – 1.11]
1.00
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Figure 1: Study population flow chart  
MOH= Medication Overuse Headache
TTH = Tension-Type Headache
1New outpatients: New patients at the LUMC outpatient headache clinic
2Excluded: No medication overuse (2a n=645 2b n=893); Age < 18 years (2a n=1 2b n=3); 
No withdrawal therapy (2a n=21 2b n=35); Withdrawal therapy elsewhere (2a n=27 2b 
n=45)
3Diagnosis MOH and advice is to withdraw medication: 3a without support by a 
headache nurse; 3b with support by a headache nurse
4Excluded: Patient is not willing to start withdrawal (4a n=5 4b n=13); Unsuccessful 
withdrawal   (4a n=15 4b n=24); Lost to follow-up (4a n=44 4b n=31)
5Successful withdrawal: 2-3 months medication- and caffeine-free period. 
6Excluded: No migraine, TTH or combination (6a n=1 6b n=2); Missing data on primary 





New outpatients 4/2008 - 3/20101b 
n = 1229 
Excluded2b n = 976
MOH + Withdrawal with headache 
nurse3b n = 253
Excluded4b n = 68  
Successful withdrawal5b 
n = 185 
Excluded6b n = 11
Complete data  
n = 174   
New outpatients 4/2006 - 3/20081a 
n = 857 
Excluded2a n = 694
MOH + Withdrawal, no headache nurse3a 
n = 163
Excluded4a n = 64 
Successful withdrawal5a 
n = 99
Excluded6a n = 6
Complete data  
n = 93
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Figure 2: The responder rate, defined as the percentage of patients with a ≥ 50% 
reduction in headache days, following medication withdrawal with and without support 
by a headache nurse, subdivided by diagnosis (N = 267). 
Responder rate group A (no headache nurse) = 35.5%, responder rate group B 
(headache nurse) = 46.0% (x² test, p = 0.098)
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TTH = tension-type headache 
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Figure 3: The mean relative reduction in headache days of successfully withdrawn 
patients and subdivided by diagnosis. (n = 242, due to missing data in 25 patients, 
one-way ANOVA: p < 0.001) 






























(N = 2 4 2 ) (N = 6 1 )(n = 9 5 )(n = 8 6 )
Error bars display standard deviations 
TTH = Tension-Type Headache 
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Abstract
Introduction
Chronic migraine (CM) is at the severe end of the clinical migraine spectrum, but 
its genetic background is unknown. Our study searched for evidence that genetic 
factors are involved in the chronification process.
Methods
We initially selected 144 single nucleotide polymorphisms (SNPs) from 48 
candidate genes, which we tested for association in two stages: the first stage 
encompassed 262 CM patients, the second investigated 226 patients with 
high-frequency migraine (HFM). Subsequently, SNPs with p-values <0.05 were 
forwarded to the replication stage containing 531 patients with CM or HFM.
Results
Eight SNPs were significantly associated with CM and HFM in the two-stage phase. 
None survived replication in the third stage.
Discussion
We present the first comprehensive genetic association study for migraine 
chronification. There were no significant findings. Future studies may benefit from 
larger, genome-wide data sets or should use other genetic approaches to identify 
genetic factors involved in migraine chronification.
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Introduction
According to the ICHD-III beta classification criteria, a clinical diagnosis of chronic 
migraine (CM) is made when a patient has 15 or more days with headache per 
month of which at least eight days have features of migraine headache (or that 
are described by the patient as migraine and are relieved by migraine-specific 
medication). (1) CM is at the severe end of the clinical migraine spectrum with 
a substantially decreased quality of life and increased disability, and is strongly 
associated with depression, medication overuse, and/or cutaneous allodynia. (2, 
3) The reported prevalence of CM is estimated to be around 0.5% to 2.0%. (4, 
5) Recently, several genome-wide association studies (GWAS) have identified a 
dozen susceptibility gene variants and loci for episodic migraine, but until now no 
studies have focused on identifying genetic risk factors for CM. (6-8) 
It is debatable whether it is meaningful to make a strict distinction between 
episodic and chronic migraine because headache frequency in patients varies 
from month to month and the thresholds of 15 headache days and eight migraine 
days, while practical, are arbitrary. (9) Genetic studies in rarer complex disease 
subtypes, such as CM, are particularly challenging as collecting sufficiently large 
numbers of well-characterized patients is difficult. Therefore, we decided to also 
include a group of patients with high-frequency migraine (HFM) that suffer from 
headache on 10 to 14 days per month, with half or more days meeting the criteria 
for migraine.
The aim of this study was to obtain evidence for association of variants in genes, 
acting in pathways possibly implicated in the chronification process of migraine as 
well as relevant secondary hits from GWA studies, with chronification of migraine. 
In total, 144 SNPs selected based on literature and previous studies were tested in 
a three-stage design. 
Methods
Participants and design of the genetic association study
Participants included in our study were patients diagnosed with either chronic 
migraine (CM) or high frequency migraine (HFM), and healthy control individuals. 
Migraine diagnoses were based on ICHD criteria. A three-stage genetic association 
study was performed (Figure 1). The discovery stage included 262 CM patients and 
2,879 control individuals (all patients came from the CHROMIG study (Spain) or 
the LUMINA study (The Netherlands)). In this stage, all 144 SNPs (in 48 genes) were 
tested. The selected markers filled one or more of the following criteria: i) SNPs 
had been positively associated to migraine and not replicated in  other migraine 
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candidate gene association studies;  ii) the corresponding genes had already 
been implicated in mechanisms relevant to the chronification of migraine; or  iii) 
SNPs were identified as secondary findings in previous migraine GWA studies. 
In the second stage, all SNPs of the first stage that showed a p-value <0.05 were 
tested in a further 226 patients diagnosed with HFM vs. the same 2,879 controls 
(patients again came from Spain or The Netherlands). In the third stage, SNPs with 
p-values <0.05 in the first two stages were tested for replication in 531 patients 
with CM or HFM (all patients came from the CHROMIG study, Spain, the LUMINA 
study, The Netherlands or the HUNT study, Norway). In this stage, 2,491 different 
control individuals from the three countries were tested.
Gene and SNP selection
We designed a candidate-gene association study focusing on genes that are likely 
associated with migraine or migraine comorbidities and may act as risk factors for 
migraine progression. To date, many association studies have been performed 
to identify genetic factors that confer susceptibility to common migraine (10, 11). 
We selected genetic variants that had been studied in Caucasian populations, 
especially those which were only studied once. According to these criteria, a total 
number of 42 SNPs in 26 genes were selected. These genes were related to: i) 
ion metabolism transport (CACNB2 and KCNB2 (12), STX1A (13), EDN1, EDNRA 
and EDNRB) (14-16); ii) dopamine (DBH) (17) and serotonin metabolism (HTR2B) 
(18); iii) hormonal metabolism (ESR1) (19-23); iv) vascular disease (IL-9, KCNK17, 
LRP1, MMP12, MTHFD1, NOS3, SCNN1A, TGFB1 and TNF) (24-26); v) autonomous 
nervous system dysfunction (GNAS1 and KCNJ1) (27, 28); vi) stress-response 
(BDNF) (29); vii)  and psychiatric disorders related genes, specially associated 
with anxiety and depression syndrome (COMT, CRY1, VIPR2, RGS2, SCN9A and 
WFS1) (30-33). In addition, we selected candidate genes that encode molecules 
known to play an important role in migraine pathophysiology but had not been 
studied before in candidate gene association studies for migraine. In more detail, 
37 TagSNPs were selected from CEU Hapmap data using a tagger pairwise 
tool with r2>0.8 (Haploview tool) that code for calcitonin-gene related peptide 
(CALCA) and its CGRP-receptor subunits (CALCRL and RAMP1). The pituitary 
adenylatecyclase-activating polypeptide (PACAP), a neuroexcitatory peptide 
released to periaqueductal gray matter during neurogenic inflammation, encoded 
by the ADCYAP1 gene, and its receptor, encoded by ADCYAP1R1, were also 
investigated with 17 tagSNPs. ESR1 and ESR2, but not GPR30 estrogen receptors, 
have been previously studied in relation to migraine, so we included GPR30, 
which encodes a multi-pass membrane protein that binds estrogen. Fractalkine, a 
chemokine that has been associated with neuroprotection (CX3CL1 gene), and its 
receptor (CX3CR1) were chosen as candidate genes with six tagSNPs(34). We also 
focused on two molecules that had previously been reported in a microarray study 
as probable migraine with aura biomarkers, namely alpha-phodrin (SPTAN1) and 
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hippocalcin-like protein (HPCAL1) (35). The former is a cytoskeletal protein of the 
spectrins family and the latter is a member of neuron-specific calcium binding 
protein family and is involved in neuronal signaling in the central nervous system. 
Two tagSNPs in both genes were genotyped. A tagSNP in peripherin (PRPH), a 
cytoskeletal protein localized in neurons of the peripheral nervous system , the 
expression of which has been associated with GPR30, was also studied (36). 
Finally, eight tagSNPs in a gene involved in circadian rhythm and metabolism 
regulation (CLOCK) were added to the panel. Overall, 77 non-previously studied 
gene variants in 12 genes were selected. 
 
Finally, 25 polymorphisms extracted from the list of secondary top hits in the 
analysis of the first migraine GWAS (6) that was carried out by our International 
Headache Genetics Consortium (IHGC) were included. The list included fifteen 
intergenic SNPs and 10 variations that were located in gene coding regions 
(ACSL5, C4Orf22, DCC, INSIG2, OPCML, OR9Q1, RELN, SMYD3, STAMBPL1 and 
TRPM8). In summary, 119 SNPs were genotyped in 38 candidate genes, as well as 
25 additional SNPs from GWAS data.
Cohorts
Spanish CM and HFM patients were recruited at the Headache Unit of the Vall 
d’Hebron University Hospital (Barcelona). Patients with CM were diagnosed by a 
clinical interview and physical examination by a headache specialized neurologist, 
according to the ICHD-III beta classification. (1) HFM was diagnosed when patients 
suffered from headache on 10 to 14 days per month, from which half or more days 
fulfilled the criteria for migraine. Healthy controls were blood donors. Exclusion 
criteria for this control population were migraine, a positive family history for 
migraine and any type of severe or recurrent headache in first-degree relatives. 
Dutch CM and HFM patients were available from the well-defined, web-based 
LUMINA population (Leiden University Migraine Neuro Analysis program) (www.
lumc.nl/hoofdpijn). Details of this study are described elsewhere. (37) Migraine 
was diagnosed according to the ICHD-III beta criteria. (1) CM was diagnosed 
when patients suffered from migraine and indicated that they experienced severe 
headache on 15 or more days per month. HFM was diagnosed when patients 
suffered from migraine and indicated that they experienced severe headache on 
10-14 days per month. Control samples for the discovery phase were part of the 
population-based Rotterdam Study. (38) Control samples for the replication phase 
were collected via a Dutch blood bank.
The Norwegian patients were recruited from the population-based HUNT-2 (1995-
97) and HUNT-3 (2006-08) studies, in which all inhabitants (age ≥20 years) of the 
Nord-Trøndelag county of Norway were invited to participate. (39, 40) Migraine 
124 | Chapter 7
was diagnosed based on a modified version of the most recent ICHD criteria at the 
time of each study, and this questionnaire-based headache classification has been 
validated by interview diagnoses. (39, 40) Migraineurs reporting headache on 7 
or more days per month were classified as HFM, and those reporting headache 
on 15 or more days per month were classified as CM. Controls were recruited 
from the same two studies, and participants fulfilling criteria for migraine were 
excluded from the control population.
Genotyping
Spanish cohorts
Venous blood samples of subjects that fulfilled inclusion criteria were collected 
in EDTA tubes and conserved at -80ºC until DNA extraction. DNA was extracted 
from blood lymphocytes at the Centre de RegulacióGenòmica (CRG, Barcelona, 
Spain) with the Chemagen® extraction kit (Perkin Elmer, Germany) and at the 
Departament de Genètica (Facultat de Biologia, Universitat de Barcelona, 
Barcelona, Spain) by a standard salting out procedure. (41) Quantity and quality 
of DNA samples were controlled spectrophotometrically with NanoDrop ND1000 
(Nanodrop, Wilmington, DE, USA).Genotyping of SNPs in the discovery sample set 
was performed with VeracodeGoldenGate technology (Illumina, CRG, Barcelona, 
Spain). For the replication phase, an additional 70 CM and HFM patients and 394 
controls were recruited under the same criteria and procedures that were used 
for the discovery sample. Blood sampling and DNA extraction were performed 
in the same way. Genotyping was performed with a Taqman® SNP Genotyping 
Assay (Applied Biosystems, Foster City, CA, USA) using the 7900HT Sequence 
Detection System (SDS, Applied Biosystems) in 384-well plates and following the 
manufacturer’s protocol.
Dutch cohort
Peripheral blood samples were collected in EDTA tubes. Subsequently, DNA was 
isolated using a standard salting out method. Genotyping of the samples had 
been previously performed as part of two genome-wide association studies for 
common migraine. (6, 7) Genotyping of the replication cohort was performed with 
a Taqman® SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA). A 
standard PCR reaction was carried out using the TaqMan Universal PCR Master 
Mix. Genotyping clusters were analysed using the Lightcycler LC-480 machine 
and LightCycler®480 1.5.0 software, version 1.5.0.39 (Roche Applied Science, 
Penzberg, Upper Bavaria, Germany) in 384-well plates following the manufacturer’s 
protocol.  
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Norwegian cohorts
DNA from all Norwegian samples was extracted from blood using two kits: 
Autopure Kit (Qiagen, Duesseldorf, Germany) and Masterpure Kit (Medinor, 
Oslo, Norway), both based on a salting out procedure.Quantity and quality of 
DNA samples were controlled regularly by monitoring every eighth sample 
spectrophotometrically with NanoDrop ND1000 and ND8000 (Nanodrop). 
Genotyping of the replication cohort was performed with a Taqman® SNP 
Genotyping Assay (Applied Biosystems). A standard PCR reaction was carried out 
using the TaqMan Universal PCR Master Mix. Genotyping clusters were analyzed 
using the Lightcycler LC-480 machine and LightCycler®480 1.5.0 software, version 
1.5.0.39 (Roche Applied Science, Penzberg, Germany) in 384-well plates following 
the manufacturer’s protocol. A part of the Norwegian sample for replication had 
previously been genotyped with the Illumina 670k platform, as part of a genome-
wide association study of migraine (8), and was used for in silico replication for the 
current study. We used the Illuminus calling algorithm, with the following filters 
for genotyped SNPs: minimum call rate per SNP and per individual (0.97), Hardy-
Weinberg equilibrium p-value higher than 1.00E-06 and MAF>0.01. For those 
SNPs that were not directly genotyped, imputation was performed with Impute 
v.2.1.2 in a standardized pipeline, using HapMap2 data from CEU population as 
the reference panel.
Statistical analyses
We performed power calculations for all three steps of our design, assuming an 
additive model, an effect allele frequency of 0.20 and effect sizes ranging from 
1.2-1.4. We added the outcome of these power calculations to the supplementary 
information. Statistical analyses were performed using PLINK v1.07 (42) and 
SNPTEST v2.2.0. (43) GTOOL v0.7.5 was used to combine different cohorts. First, 
the entire panel of SNPs was tested for the Hardy-Weinberg equilibrium (HWE) for 
each cohort considering p<0.05 as the threshold. Then, both allele and genotype 
frequencies were compared between cases and controls, considering additive, 
genotypic (co-dominance), dominant and recessive models. Subsequently, a 
meta-analysis was performed using GWAMA v2.1. For all analyses, the threshold 
for statistical significance was defined as a p-value below 0.05. Approval was 
obtained from local medical ethics committees and written informed consent was 
obtained from all participants.
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Results
For this study, 144 SNPs in genes already implicated in migraine or that had 
surfaced as interesting secondary hits in GWA studies (see Supplementary 
Data) were used in a three-stage association design (Figure 2). In the first stage, 
SNPs were tested in 262 patients with CM vs. 2,879 control individuals. Nominal 
significant associations (p-value <0.05) were obtained for 30 SNPs (see also 
Supplemental Table 2). These 30 SNPs were taken forward to the second stage with 
226 patients with HFM and the same control data set, where eight SNPs showed a 
nominally significant association; rs5742912 (in SCNN1A), rs3792603 (in CLOCK), 
rs2956 (in CALCA), rs858745 (in CALCRL), rs302680 (in RAMP1), rs2267730 and 
rs2299908 (in ADCYAP1R1), and rs217693 which is an intergenic SNP. These eight 
SNPs were taken forward to the replication stage and were genotyped in three 
replication cohorts from Spain (70 patients with CM or HFM and 394 controls), The 
Netherlands (210 patients with CM or HFM and 896 controls), and Norway (162 
patients with CM or HFM and 495 controls).The availability of GWA data allowed 
testing of seven of the eight SNPs in 89 additional Norwegian patients with CM or 
HFM and 706 controls. Subsequently, a combined meta-analysis of the association 
results from these replication cohorts with 531 patients with CM or HFM and 2,491 
controls was performed but showed no statistically significant associations. 
Discussion
Here we present the first comprehensive genetic association study in chronic 
and high-frequent migraineurs testing 144 SNPs from 48 genes in 1,019 patients 
with chronic or high frequency migraine, without significant associations. Patient 
numbers in each cohort were relatively small, largely because of the rarity of 
chronic migraine, which makes it difficult to collect large enough patient samples. 
As (chronic) migraine is a complex genetic disorder, it is likely that multiple genetic 
variants, each with relatively small effect, contribute to disease susceptibility, 
suggesting that large numbers of patients and controls are needed to reach 
sufficient power to detect a genetic association. We attempted to address this 
challenge in two ways. First, to increase overall numbers, we decided not t only 
to include chronic migraine patients, but also high frequency migraineurs, as we 
consider the cut off values for a diagnosis of chronic migraine rather arbitrary and 
instead favour the idea that migraine chronification has a broader spectrum with 
respect to the number of headache days.(9) Second, by selecting only candidate 
genes (and SNPs therein) we reduced the massive correction for multiple testing 
that is needed for unbiased genome wide association approaches. Considering 
the negative results, our approach may still have had insufficient statistical power 
or we may have selected SNPs irrelevant to migraine chronification. As even 
large international collaborations, such as the International Headache Genetics 
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Consortium (IHGC), have difficulties to collect large enough cohorts of well-
characterized patients with chronic and high frequency migraine, we feel that 
studies like ours will probably remain underpowered in the immediate future. We 
are working in the International Headache Genetic Consortium on unifying the 
criteria to select patients so that future studies will be able to count on larger and 
better phenotyped cohorts.
Chronic migraine is severely disabling and difficult to manage, as affected patients 
experience substantially more-frequent headaches, comorbid pain and affective 
disorders, and fewer pain-free intervals, than do those with episodic migraine. 
(4) Furthermore, the relationship of chronic migraine with cutaneous allodynia 
has been investigated, indicating that cutaneous allodynia is a clear risk factor 
for migraine chronification. (3) Different models have been proposed to explain 
this relationship. Further investigations in the basic mechanisms of cutaneous 
allodynia, and its relationship with migraine chronification, could lead to new 
potential genes which should be studied in future designs. 
Clinical and genetic studies have shown that migraine is a multifactorial disorder 
with complex interaction between multiple predisposing genetic and modulating 
non-genetic factors.  GWAS have identified 13 gene variants pointing, among 
others, at pathways involved in glutamatergic neurotransmission and synaptic 
function. (8) Translating results from GWAS to pathophysiological mechanisms, 
however, remains one of the biggest challenges in molecular biology as gene 
effect sizes are small and their interactions are complex.
We suggest that for future designs it is relevant to consider the outcome of 
withdrawal from medication, as the vast majority of CM patients is (over)using 
acute headache medication. In this study, we did not have sufficient data to include 
this aspect in the analysis. However, future studies would benefit from subdividing 
chronic migraineurs into patients responsive to withdrawal therapy and returning 
to episodic migraine after withdrawal of their medication, and patients in which 
such withdrawal has no or less effect on attack frequency. Lastly, although the 
problem of statistical power will remain problematic in association studies for 
chronic and high frequent migraine, we would like to put forward that perhaps 
other genetic approaches are more fruitful in detecting genes and pathways 
involved in chronic migraine, such as gene expression studies, epigenetic studies 
or the analysis of rare variants.
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Figure 2: SNP selection study flow
* 16 SNPs excluded due to genotyping failure, low HWE, or low rate of successful genotypes. 
Nominally significant: p< 0.05
144 candidate SNPs
128 SNPs left * 
 
tested in 262 CM patients vs. 2,879 
controls
30 SNPs nominally significant in stage 
1 
tested in 226 HFM patients vs. 2,879 
controls
8 SNPs nominally significant in stage 
1 and 2 
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Genomic position in basepairs according to Build 37. 
Ref. allele, Reference allele; Alt. allele, Alternative allele; OR, odds-ratio; CI, confidence 
interval. 
Stage 1 included 262 CM cases and 2879 controls, stage 2 included 226 HFM cases 
and 2879 controls (same controls as stage 1), stage 3 included 531 CM/HFM cases and 
2491 controls
Effects: Direction of individual effects in the four replication cohorts, depicted in the 
following order: Spanish CHROMIG (Taqman) / Norwegian HUNT (in silico) / Norwegian 
HUNT (Taqman) / Dutch LUMINA (Taqman). (+) risk addition; (-) risk reduction; (?) not 
calculated (due to missing data).
Supplemental Information
Supplemental table 1: power calculations
Stage 1:













































































MAF= minor allele frequency
CM/HFM= chronic/high frequency migraine patients
RR= Relative Risk
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Abstract
Objectives
As cluster headache (CH) is often referred to as ‘suicide headache’, we wanted 
to assess the prevalence of depression in cluster headache patients, and to 
investigate determinants of depression such as sleep disturbances. 
Methods
In a cross-sectional, web-based, validated questionnaire study among 462 
well-defined CH patients and 177 controls, we diagnosed CH according to 
the International Classification of Headache Disorders (ICHD-III). We assessed 
depression using the Hospital Anxiety and Depression Scale (HADS-D) and the 
Center for Epidemiologic Studies Depression scale (CESD) with supplementary 
questions to assess lifetime depression. Data were analysed with logistic and 
linear regression models.
Results
Lifetime depression showed almost three times higher odds in CH patients 
(n=462) than controls (n=177) (OR 2.77, 95% CI 1.70-4.51). Chronic (n=67) vs. 
episodic (n=394) patients had a higher prevalence of lifetime depression and 
more sleeping problems. Current depression was associated with having active 
attacks (last attack < 1 month) (adjusted p=0.02), but no effect remained after 
correction for sleep disturbances. 
Conclusion
Cluster headache is associated with an almost three times increased odds of 
lifetime depression. Current depression is highly prevalent in patients with active 
disease, in part related to sleep disturbances due to current nocturnal attacks.
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Introduction
Cluster headache (CH) is a highly disabling headache disorder, typically 
represented by frequently recurring attacks of 15-180 minutes of unilateral, peri-
orbital, excruciating pain associated with ipsilateral facial autonomic features 
and restlessness. (1) Nocturnal sleep-related attacks are highly prevalent, with 
75% of all attacks starting between 9:00 pm and 10:00 am, leading to impaired 
sleep quality and quantity. (2) In about 85% of patients, headache attacks cluster 
in periods of several weeks to months, interspersing with attack-free periods of 
several months to years (episodic CH); in the remaining patients, long attack-free 
periods are absent (chronic CH). (1, 3, 4) The lifetime prevalence of CH is about 
one in 1000 with a male to female ratio is 4.3). (4, 5)  Related to the low prevalence, 
many patients are diagnosed only after many years. (6, 7)  The reduction of quality 
of life, social functioning, and socioeconomic status can be enormous in CH 
patients (depending on subtype, number of cluster periods, attack frequency, and 
response to treatment). (8)
Patients portray the excruciating pain of a cluster headache attack as being worse 
than any other pain they have ever experienced. The extreme nature of the pain 
has earned CH the title ‘suicide headache’. Suicidal tendencies have been reported 
in 25-55% of patients. (9-11) 
CH shows several clinical, therapeutical and pathophysiological similarities to 
migraine, another episodic headache disorder. Prospective long-term follow-up 
studies in patients with migraine and in patients with depression have shown that 
the risk of depression is increased in patients with migraine and vice versa the risk 
of migraine is increased in patients with depression. (12, 13) Such bidirectional 
comorbidity suggests shared underlying pathophysiological, possibly genetic 
mechanisms for both episodic brain conditions. (14, 15) Furthermore, many CH 
patients have a lack of sleep due to nocturnal attacks, potentially contributing 
to depressive symptoms. Previous small studies investigated the relationship 
between cluster headache and depression, but did not use specific and structured 
questionnaires for establishing a diagnosis of CH or depression. (10, 16, 17) We 
therefore wanted to assess whether depression is also a comorbid condition 
in CH. To this end we interviewed 462 well-characterized CH patients from the 
Leiden University Cluster Headache Analysis programme (LUCA) using validated 
questionnaires, and compared the results with those of 177 non-headache 
controls. Secondarily, we wanted to identify CH specific characteristics that are 
associated with depression.
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Methods
Participants and study design
The present study was conducted as part of the LUCA project (Leiden University 
Cluster headache Analysis programme), the details of which have been reported 
elsewhere. (18) In brief, using a dedicated website and two validated web-based 
screening and diagnostic questionnaires, with a specificity of 88% to diagnose CH 
according to the International Classification of Headache Disorders (ICHD-III beta) 
criteria, (1) Dutch speaking persons between 18 and 80 years of age from The 
Netherlands were invited to participate in research on CH. A clinically confirmed 
diagnosis of cluster headache by a physician was available for 94% of the LUCA 
population. (18) For the remaining 6%, no clinically confirmed diagnosis was 
available, for instance because they never consulted a doctor. The questionnaires 
included, in addition to diagnostic questions, also questions regarding 
demographic factors, use of acute and prophylactic headache medications, and 
CH attack frequency.  The CH questionnaire primarily was validated for the ICHD-II 
criteria for cluster headache. (18, 19) Recently, however, new ICHD-III criteria have 
been published, which have been shown to have no differences to the validity of 
the CH questionnaire. (20) Therefore, our diagnoses fulfil the ICHD-III criteria for 
CH.
Non-headache individuals willing to participate had to pass a screening 
questionnaire online via the research website. If this screening questionnaire did 
not show any indication for having migraine, cluster headache, chronic tension type 
headache or medication overuse headache, individuals were sent a subsequent in 
depth questionnaire. This second questionnaire again assessed possible headache 
complaints, together with demographic variables. Only individuals that fulfilled 
both the criteria of ‘non-headache’ in the screening and in depth questionnaire 
were considered eligible controls and were approached for this questionnaire 
study. Healthy controls were also sent web-based questionnaires on symptoms 
of (lifetime) depression, sleeping problems and demographic characteristics, 
identical to the questionnaires that were sent to the CH patients. 
All patients diagnosed with CH and controls received an invitation to participate 
in a questionnaire with questions on symptoms of lifetime depression and 
sleeping problems. For all questionnaires, non-responders received two e-mail 
reminders. Participants without the needed internet skills were able to fill out the 
questionnaires on paper. 
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Standard Protocol Approvals, registrations, and patient consents
The LUCA and depression studies were approved by the Medical Ethics Committee 
of the Leiden University Medical Center. All participants provided written informed 
consent. 
Measures
The extended CH questionnaire included questions which allowed to divide 
between chronic (no attack-free periods of more than one month) and episodic 
(attack-free periods) CH, and to indicate whether the CH was ‘active’ (last attack 
< 1 month ago) or the participant was ‘attack-free’ (last attack > 1 month ago). 
For episodic CH patients questions were asked on the mean frequency of attacks 
during the start-up phase, the bout and the recovery phase. Also, the mean 
duration of the remission phase was asked. For chronic CH patients the mean 
number of attacks per day was asked. We defined four groups of patients: 1) 
episodic active; 2) episodic attack-free; 3) chronic active; 4) chronic attack-free. 
The latter group is considered to be treated successfully for their chronic CH, 
although a return to episodic CH (‘secondary episodic’ CH) cannot be excluded. 
In order to be able to adjust for potential confounding effects of demographic 
variables and addictive behaviour, questions were asked on gender, age, marital 
status, ethnicity, education, body mass index (BMI), smoking, caffeine use and 
alcohol consumption. 
Lifetime depression was measured as a dichotomous variable. We used validated 
cut-off scores for the depression subscale of the Hospital Anxiety and Depression 
Scale (HADS-D) and the Centre for Epidemiologic Studies Depression scale (CESD), 
in combination with a previously used and published algorithm for depression 
and an additional question on depression diagnoses in the past: [HADS-D ≥ 8, or 
CES-D ≥ 16, or use of antidepressants with as indication a depression, or having 
had the diagnosis depression in the past]. (14, 15, 21, 22) Both CH patients and 
controls filled out the same depression questionnaires, whereas the CH patients 
filled out additional questions on current headache status at the time of the 
depression questionnaire. 
To correct for a potential confounding effect of sleep disorders, the Pittsburgh 
Sleep Quality Index (PSQI) was used to measure sleep disturbances over the past 
month. The PSQI is designed to measure the quality and patterns of sleep in the 
past month and contains 19 self-rated questions, with a global scoring range of 0 
to 21. Higher scores denote a poorer sleep quality. (23) Scores are also allowed 
to be dichotomized, with a score of >5 defining ‘poor sleepers’. CH patients and 
controls filled out the same questionnaire.
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Statistical method
We reported baseline characteristics as mean ± standard deviation (SD) or 
percentages. Differences in means between CH and control groups were tested 
with 2-sided independent samples t-tests. Differences in proportions were tested 
by x2 tests. We conducted a univariate logistic regression model to test the crude 
association between the presence of CH and the odds of being depressed. 
Analyses were rerun, adjusting for gender, age, education and BMI (model 1), and 
additively adjusting for PSQI-score (model 2). Results were reported as odds ratios 
with 95% confidence intervals and corresponding p-values. Secondarily, baseline 
characteristics of the different CH subtypes (episodic/chronic, and active/attack-
free) were reported as mean ± SD or percentages. We tested differences in means 
between CH subgroups with one-way ANOVAs or independent samples t-tests. 
Differences in proportions were tested using x2 tests. A univariate linear regression 
model was conducted to test the crude association between the CH status (active/
attack-free) and the score on the HADS-D depression questionnaire. Here also, 
analyses were rerun, adjusting for gender, age, education and BMI (model 1), for 
subtype (chronic/episodic) (model 2) and for PSQI-score (model 3). Subsequently, 
we investigated associations with current antidepressant use and current lithium 
use in an additional model. Results were reported as unstandardized regression 
coefficients (B) with 95% confidence intervals and corresponding p-values. For all 
analyses p-values of <0.05 were considered to indicate statistical significance. We 
performed all analyses by SPSS 17.0 (SPSS inc., IBM, USA).
Results
Study flow and descriptives
The total study flow is shown in figure 1. All eligible persons with CH within the 
LUCA database (n=528) received a depression questionnaire (mean age ± SD: 
48.8 ± 11.7), of which ultimately 467 returned questionnaires (88.4% response 
rate). The primary analysis was conducted in 462 participants with CH, because 
of missing demographic data in 5 patients. Responders (n = 462) did not differ 
from non-responders (n = 66) for age or gender.  The secondary analysis was 
conducted in 461 participants with CH because of missing attack frequency data 
in one subject. Of the 252 controls in the LUCA database (mean age ± SD: 45.0 ± 
14.3), n=177 (70.2%) filled out a depression questionnaire. Responders (n=177) 
were slightly older than non-responders (n=75), (46.6 years v. 41.3 years; p = 
0.006), but did not differ in gender (supplementary tables e-1, e-2. e-3).
Descriptive data for participants with CH and non-headache controls are shown in 
Table 1. The 462 CH participants differed on several variables from the 177 healthy 
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controls. CH participants more often were males and married, were slightly older, 
had a lower educational level and slightly higher BMI, smoked substantially more 
pack years, and tended to use more caffeine. Furthermore, they showed increased 
scores on depression and anxiety scales and were more likely to report increased 
use of antidepressants, having received a diagnosis of depression in the past and 
experiencing sleeping problems.
The association between CH, depression and sleep disturbances
Participants with CH scored higher on all different subscales of the depression 
questionnaires, more often had lifetime depression and more often used or had 
used antidepressants (table 1). They also scored higher on the PSQI questionnaire 
(indicating worse sleep quality), and more often could be qualified as ‘poor 
sleeper’. As shown in table 2 and figure e-1, the logistic regression analyses of 
the association between CH and the odds of depression showed in the crude 
model, an odds ratio of 4.17  compared with controls. This effect remained largely 
unchanged when adjusted for the covariates gender, age, education and BMI (OR 
4.08). After adjustment for PSQI-score, the odds ratio remained increased (OR 
2.77). 
Baseline comparison of CH subtypes
CH participants (n=461) were divided in the following groups: 1) episodic active 
(n=106); 2) episodic attack-free (n=288); 3) chronic active (n=58); 4) chronic attack-
free (n=9). Differences in alcohol use, duration of attack-free periods, time to last 
attack and all different depression and sleep subscales were observed. In general, 
participants with chronic CH had more symptoms of depression, and worse sleep 
quality, when compared to participants with episodic CH (table 3). 
The association between active CH and current depression
As shown in table 4 and figure e-2, participants with active CH scored 1.81 
points higher on the current depression questionnaire (HADS-D) than attack-
free CH patients. This effect remained after adjustment for covariates gender, 
age, education and BMI (model 1). After adjustment for CH subtype (episodic 
or chronic), the effect decreased (B -1.02) (model 2). After adjustment for PSQI 
score (model 3), no effect remained (B -0.04). These results indicate an association 
between the current activity of CH and current depression, with involvement of 
current sleep disturbances.
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Determinants of depression in CH patients
As shown in table 4, model 3, determinants of current depression in  CH participants 
were: a lower educational level, having chronic CH  and a higher PSQI sum 
score. Use of lithium might indicate more severe cluster headache (as it may be 
prescribed as a second line prophylactic treatment), more severe depression (as 
it may be prescribed as an additive to antidepressants if other treatments fail), or 
both. Additional analyses of current use of lithium  indeed showed an association 
with depression scores, without changing the p-values for the other determinants. 
Subsequent analyses with current antidepressant use showed an association with 
depression scores, without changes in the significance of p-values of the other 
determinants.
Discussion
This is a large study on the prevalence of depression in a large sample of patients 
with cluster headache (CH).
CH patients had three times higher odds for depression than controls.  Patients 
with active or chronic CH had higher depression scores than patients with CH who 
were attack free. Our finding that CH is associated with increased prevalence of 
depression is well in line with results from earlier smaller studies which, however, 
did not use specific and structured questionnaires for CH and depression. (10, 16, 
17) Considering that depression is more prevalent among women and that there 
were proportionally much fewer women in the cluster headache sample than in 
the control group, the increased prevalence of depression in cluster headache is 
even more striking.
We can only speculate on why CH patients have increased prevalence of 
depression. As 85% of participants with CH had nocturnal attacks, lack of sleep 
might have been a contributing factor. Despair and stress because of relentlessly 
recurring pain attacks is another possible factor. Finally, hypothalamic dysfunction 
may offer a good explanation as depression (24), sleep disorders (25) and CH (26-
28) have been associated with both functional and structural changes in this part 
of the brain. Epidemiological associations with depression have been described 
for a range of neurological disorders, in particular those associated with chronic 
pain. (29) Whether and to what extent the underlying mechanisms are similar 
remains to be studied.
Depression in cluster headache patients is at least partially explained by poor sleep 
quality. The odds ratio for depression dropped from 4.17 to 2.77 after adjustment 
for sleep disturbances. Current attacks of cluster headache was associated 
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with current depression, but this effect disappeared after adjustment for sleep 
disturbances. Participants were not wrongly considered as depressed due to 
sleeping problems, as the HADS questionnaire, in contrast to other instruments 
that measure depressive symptoms, contains no questions about this issue. It 
seems more likely that CH, depression and sleeping disturbances are intertwined. 
There is evidence that sleeping problems can be a risk factor for depression (30), 
and sleeping problems in cluster headache patients are caused by CH attacks that 
typically occur at night.
Another striking and clinically potentially relevant finding of our study was that, in 
all likelihood, depression was considerably underdiagnosed and undertreated in 
cluster headache patients. Only 23/133 (17%) of the 133/462 (28%) participants 
with cluster headache who fulfilled the loose criterion for current depression 
(HADS-D ≥ 8) and only 14/56 (25%) of the 56/462 (12%) participants who fulfilled 
the stricter criterion for current depression (HADS-D ≥ 11) were treated with 
antidepressants. 
Our data suggest that current attacks are associated with increased symptoms of 
depression, and worse sleep quality. Therefore, we may conclude that unsuccessful 
treatment of cluster headache is associated with poor outcomes: depression 
and sleeping problems. This underlines the importance of adequate treatment 
for cluster headache. Suicidal thoughts are frequently reported in patients with 
cluster headache and could be related to the higher frequency of depression. 
(10, 11) Unfortunately we have no information on suicidal thoughts in our study 
population, but this would be an important topic for future research.
In patients with migraine, comorbid depression is a risk factor for migraine 
chronification. (15, 31, 32) Interestingly, in the present study, participants with 
chronic CH scored substantially higher on all depression subscales than those with 
episodic CH. However, due to the cross-sectional nature of our study, we cannot 
distinguish between cause and consequence. Likewise, we cannot determine 
whether depression and CH show bidirectional comorbidity. This would require 
long-term, prospective follow-up studies which are challenging because of the 
low incidence and prevalence of CH. 
Strengths of our study include the large sample size for such a rare condition,  the 
use of validated diagnostic questionnaires for CH (18) and the detailed information 
on depression. Head trauma has been associated with both depression and, in 
a few cases, cluster headache. (33, 34) The evidence for a causal relationship 
between head trauma and cluster headache is, however, limited and the relation, 
if any, seems rare. We therefore believe that the lack of information on a history 
of head trauma is unlikely to have affected the results. Possible limitations of our 
study are that our LUCA population is predominantly Dutch/Caucasian, of relatively 
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young age, recruited via the internet, and on average well-educated. We therefore 
cannot extrapolate our studies to other ethnic groups or populations from different 
socio-economic backgrounds. Also, in line with previous epidemiological studies, 
participants with CH more frequently were male and heavy smokers than non-CH 
controls. (5, 11) It seems unlikely that these differences have materially affected 
the results, as we adjusted all analyses for these differences.  Another possible 
limitation is that depression was measured with questionnaires which are not 
specifically designed to diagnose clinical depression in individuals. However, 
we used validated cut-off values, which should provide a reliable differentiation 
between depressive and non-depressive persons. (21, 22) Cluster headache 
patients showed increased anxiety which might have contributed to the increased 
comorbid prevalence of depression. Unravelling the exact role of anxiety should be 
a topic of future research. Lastly, due to the cross-sectional character of this study 
no firm conclusion could be drawn regarding the direction of the comorbidity. 
Early detection of comorbid depression in cluster headache may be important to 
prevent suicide in this unbearably painful primary headache disorder. Longitudinal 
bidirectional follow-up studies, although challenging, will be necessary to 
investigate the relationship in time between CH and depression, to answer the 
question on causal relationship.
  8









































































































































































































































































148 | Chapter 8
Table 1: Baseline characteristics of study population and comparison between 462 CH 






































Caffeine (units per day) 














Ever antidepressants (% yes)
Current antidepressants (% yes)
Ever diagnosis depression (% yes)

































CH, Cluster Headache; BMI, Body Mass Index; HADS, Hospital Anxiety and Depression 
Scale (D: depression scale; A: anxiety scale); CES-D, Centre for Epidemiologic Studies 
Depression Scale; PSQI, Pittsburgh Sleep Quality Index. Values are percentages or 
means ± SD. P-values depicted in bold indicate a statistical significant difference, using 
x2 tests and independent samples t-tests appropriately.
* Poor sleeper defined as PSQI-score >5
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Table 2: Logistic associations between CH and lifetime depression in 462 participants 
with CH and 177 controls.
OR 95% CI p-value
Univariate association
Model 1
Adjusted for gender, age, education, BMI
Model 2










Data are Odds Ratios (OR) with 95% confidence intervals and p-values. Model 1 was 
adjusted for gender, age, education and BMI. Model 2 was additively adjusted for 
PSQI-score. Values depicted in bold indicate statistical significant results.
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Number of attacks per 
day (bout)






























































































Cluster headache and depression | 151 
BMI, Body Mass Index; CCH, Chronic CH; ECH, Episodic CH; HADS, Hospital Anxiety 
and Depression Scale (D: depression scale; A: anxiety scale); CES-D, Centre for 
Epidemiologic Studies Depression Scale; PSQI, Pittsburgh Sleep Quality Index. Active, 
last attack ≤1 month; Attack-free, no attacks for > 1 month. Values are percentages or 
means ± SD. P-values depicted in bold indicate a statistical significant difference, using 
x2 tests and independent samples t-tests appropriately.
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Table 4: Linear associations between CH status (active / attack-free) and current depression 
(HADS-D scores) in 461 participants with CH.
B 95% CI p-value
Univariate association
 CH status (attack free vs. active) -1.81 -2.62 - -1.00 <0.001
Model 1
 CH status (attack free vs. active)
 Gender (female vs. male)
 Age


















 CH status (attack free vs. active)
 Gender (female vs. male)
 Age
 Years of education
 BMI




















 CH status (attack free vs. active)
 Gender (female vs. male)
 Age
 Years of education
 BMI
 CH subtype (chronic vs. episodic)
 PSQI sumscore
 Subsequent analyses*:
 Current lithium use




























Data are unstandardized regression coefficients (B) with 95% confidence intervals 
and p-values. Model 1 was adjusted for gender, age, education and BMI. Model 2 
was additively adjusted for CH subtype (chronic/episodic). Model 3 was additively 
adjusted for PSQI-score. Values depicted in bold indicate statistical significant results.
* Subsequent (separate) analyses with current lithium use and current use of antidepressants 
showed no changes in the significance of the other determinants.
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9.1 Summary 
In chapter 1 I provide a general introduction in the topic of this thesis. It describes 
epidemiology, criteria, pathophysiology, genetics and treatment of migraine and 
depression, and also migraine chronification and the role of medication overuse. 
Furthermore, an introduction in comorbidity of both diseases is given, focusing 
on what we know already, and specific remaining questions to be answered in this 
thesis. 
In chapter 2, I describe that 45% of migraineurs fulfilled the criteria for lifetime 
depression. A high migraine attack frequency and the presence of cutaneous 
allodynia were migraine specific factors associated with an increased prevalence 
of depression. Furthermore, being a poor sleeper, female gender, high BMI, being 
single, smoking, and a low alcohol consumption were general determinants of 
depression in our population. This study identified allodynia, in addition to high 
migraine attack frequency, as a new migraine specific factor associated with 
depression. 
In chapter 3 I essay that cutaneous allodynia was highly prevalent in our migraineurs: 
70% reported allodynia during migraine attacks. Allodynia was associated with the 
presence of depression, and also with female gender, low age at onset, and high 
migraine attack frequency. Analysis of the longitudinal data showed that allodynia 
was an independent predictor for increase in migraine frequency.
In chapter 4, I show that hemiplegic migraine patients had increased odds for 
lifetime depression compared with controls. Use of acute anti-migraine medication 
was associated with lifetime depression.
In chapter 5, I describe that migraine patients differed significantly from healthy 
controls on all 3 dimensions of affective disorders: lack of positive affect, 
somatic arousal, and negative affect. For the lack of positive affect and negative 
affect dimensions, migraine patients were predominantly similar to a ‘past 
psychopathology’ group. For the somatic arousal dimension, migraine patients 
scores were more comparable with a ‘current psychopathology’ group.
Chapter 6 provides evidence that successful withdrawal from medication overuse 
was significantly higher in the group supported by a headache nurse than in the 
group without support. Support by a headache nurse was not associated with 
response (≥ 50% reduction in headache days after successful withdrawal). The 
underlying headache primary headache diagnosis, determined after withdrawal, 
was significantly correlated with response (with increased response in the group 
with underlying migraine, when compared with the group with tension type 
headache). 
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I describe a study in chapter 7 which aimed to search for evidence that genetic 
factors are involved in the chronification process of migraine. No loci survived 
replication, which left us without significant findings. 
In chapter 8 I show that 44% of cluster headache patients fulfilled the criteria 
for lifetime depression. Chronic vs. episodic patients had a higher prevalence 
of lifetime depression and more sleeping problems. Current depression was 
associated with having active attacks, but no effect remained after correction for 
sleep disturbances. 
9.2 General Discussion and future perspectives
9.2.1 Clinical determinants of depression in migraine patients
A broad range of studies, with mostly cross-sectional and sparsely longitudinal 
designs, have been published on the topic of migraine and depression.  (1-14) 
Chapter 2 showed that our population of migraine patients was comparable 
to other studies with respect to the prevalence of lifetime depression (varying 
from 20% to 60%). The quality of migraine characterization and depression 
characterization, however, has in most of the previous studies been moderate, if 
not poor. A major strength of our study, and a clear difference with most earlier 
published studies, is the extensive characterization of patients. We could show 
clear associations with a large number of determinants. This detailed information 
on clinical and socio-demographic variables allowed for specific subsequent 
studies, with broad opportunities for statistical adjustment to prevent bias. The 
question could be raised whether the found association might be the artefact of 
our definitions. A part of the comorbidity between migraine and affective disorders 
could be due to overlapping symptomatology, as some of the characteristic 
features of migraine attacks, such as nausea, loss of energy, anhedonia, and sleep 
disturbances, could lead to misclassification of depressive disorder in migraine 
patients. However, the association of migraine and depression is still present when 
questionnaires focusing on the non-somatic aspects of depression are applied, 
such as the Hospital Anxiety and Depression Scale. (15) Furthermore, the robust 
trend in published literature on the issue of migraine and depression is that, 
irrespective the extensiveness of the depression characterization, all studies show 
an association. In our opinion, this strongly suggests that we have confirmed a real 
association between 2 genuine disorders.
9.2.2 High migraine attack frequency is associated with depression
We identified migraine frequency to be associated with depression (chapter 2), 
which confirmed findings from two other studies with poor characterization of 
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depression. (16) (17) The direction of this causation in our study remained unclear 
due to its cross-sectional character. We addressed this problem in chapter 3. There 
we showed that lifetime depression at baseline was associated with an increase in 
migraine days over a median follow-up period of 2 years. These findings confirm 
that depression is a risk factor for migraine chronification. 
9.2.3 Genetic factors involved in migraine and depression
As it remains unclear which specific genetic factors are involved in the increased 
liability to migraine and depression (11, 18), we performed a GWAs study to 
identify shared genetic factors for migraine and depression (not presented in 
this thesis). A total of 1450 migraine patients of our LUMINA cohort had migraine 
and depression, of which GWAs data was obtained for 598 patients. A GWAs 
study was performed for these patients and combined with GWAs data of three 
additional cohorts in a meta-analysis for migraine and depression. This resulted 
in 4 peaks (loci) that reached the threshold of suggestive significance. The study 
included a total amount of 1700 cases and 5600 controls. Four study samples 
were made available for replication, and 20 SNPs located in these four top loci 
were genotyped in these cohorts using the Sequenom technique. Unfortunately, 
we could not replicate our initial findings. The negative outcome in our first GWAs 
on migraine and depression is less surprising in view of findings in GWAs studies 
of depression, where only the latest GWAs in June 2016 provided first evidence of 
genetic factors in depressive symptoms in large amounts of cases. (19) Regardless, 
our approach to test migraine and depression combined (as an endophenotype) 
may yield more positive results, although the challenge seems considerable. 
To increase power, we increased our sample size by adding new cohorts to our 
discovery sample. Additional GWAs for migraine and depression are currently 
being performed. Hitherto we have not been able to present or definitely refute 
evidence from genetic studies that migraine and depression share an aetiological 
basis.
9.2.4 Cutaneous allodynia is associated with migraine chronification
The study described in chapter 2 was the first to identify cutaneous allodynia as 
a determinant of lifetime depression in migraineurs. The prevalence of allodynia 
in our study is in line with all previous studies on allodynia in migraine (ranging 
from 50% to 80%). (20) Migraine, depression and allodynia are intertwined, and 
allodynia plays an important role in the migraine triad of chronification, depression, 
and medication overuse. As cutaneous allodynia is considered a clear marker for 
a central sensitization process of the brain, (21) this finding could shed new light 
on the pathophysiological mechanisms behind the relationship between migraine 
chronification and depression.
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Chapter 3 shows that recurrent migraine with cutaneous allodynia probably leads 
to a decreased threshold for subsequent migraine attacks. A possible explanation 
may be that repetitive activation of trigeminovascular neurons and of modulatory 
pain pathways may lead to impairment of function or neuronal cell damage in brain 
areas involved in migraine generation. This might lead to decreased thresholds for 
activation, leading to chronification of migraine. (20, 22) Another concept is that 
of nociception-induced plasticity, suggesting that kindling and related models 
of neuroplasticity can be used to describe ways in which exposure to a noxious 
stimulus may, under certain conditions, lead to a permanently sensitized state, and 
to chronification of pain. (23)
The finding that repeated migraine attacks increase the susceptibility for 
subsequent attacks, which may also lead to structural and functional changes 
within pain pathways, could in the future also be validated in wild type mice and 
our transgenic knock-in migraine mouse models that harbour human pathogenic 
mutations for familial hemiplegic migraine. (24-26) These mice exhibit increased 
neuronal calcium influx and glutamatergic neurotransmission, resulting in lowering 
of the induction-threshold for cortical spreading depression and an increase of 
the frequency of cortical spreading depression. By repeating induced cortical 
spreading depression, it could be determined whether there is a critical window 
for chronification. Daily administration of analgesics or triptans could possibly 
induce a state comparable to medication overuse headache. Study designs with 
an experimentally evoked anhedonic depressive-like status could investigate the 
relationship between anhedonia and sensitivity for cortical spreading depression. 
Measurements of cutaneous allodynia have been performed before in mice, 
and could be associated with the sensitivity for cortical spreading depression. 
Altogether, mouse models could provide supporting evidence and new insights 
about the relationship between migraine chronification, cutaneous allodynia, and 
depression.
9.2.5 Dimensions of affective disorders in migraine patients
Not only migraine, but also several other somatic disorders (like diabetes, obesity, 
and cardiovascular disease) show increased associations with the somatic-affective 
dimension rather than cognitive-affective symptoms of affective disorders, as 
described in chapter 5. (27-30) Therefore, it has often been hypothesized that the 
association between a somatic disease and depression is primarily through the 
somatic-affective dimension of depression, the so-called somatic depression. (31, 
32)
One might argue that we did not find a comorbidity between migraine and 
depression, but between migraine and ‘feeling unwell’, as a consequence of the 
somatic disease. We would however like to object to this argumentation. First, the 
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source papers for the relationship between migraine and depression have been for 
years the longitudinal studies of Breslau et al. (1, 2) These papers describe not only 
an increased risk of first onset depression in migraine patients, but also vice versa 
an increased risk of first onset migraine in patients with a depression. This argues 
against depressed feelings following (frequent) migraine attacks. Furthermore, 
chapter 5 clearly shows that the symptom profile of affective disorders in migraine 
patients differs from healthy controls for all three dimensions of the MASQ-D30 
questionnaire, not only for the somatic arousal dimension. Therefore, our study 
shows that affective disorders in migraine patients cannot be fully explained by 
somatic depression or overlapping symptomatology. 
Our study shows an even stronger comorbidity between migraine and symptoms 
of anxiety, than between migraine and symptoms of depression per se. This is 
particularly interesting, since most studies hitherto focused on the comorbidity 
between migraine and depression, whilst the comorbidity of migraine and anxiety 
is a largely unexplored area. Our study shows that anxiety arousal might be the 
corresponding component, but the underlying mechanism should be further 
investigated. 
9.2.6 Depression in hemiplegic migraine 
Our finding from chapter 4 that the lifetime prevalence of depression in patients 
with hemiplegic migraine compares to the prevalence found in migraineurs with 
and without aura (chapter 2), fits well with the hypothesis that hemiplegic migraine 
is part of the migraine spectrum. (33) Probably the same pathophysiological 
mechanisms play a role in the comorbidity of depression with migraine with and 
with aura at the one hand, and hemiplegic migraine at the other.
The genes involved in hemiplegic migraine may, directly or indirectly, make 
patients more susceptible to depression (chapter 4). Hitherto three genes have 
been identified for hemiplegic migraine. FHM1 is caused by missense mutations 
in CACNA1A on chromosome 19p13. (34) FHM2 is caused by missense mutations 
in ATP1A2 on chromosome 1q23. (35) FHM3 is caused by missense mutations 
in SCN1A on chromosome 2q24. (36) The functional effects of FHM1, FHM2 and 
FHM3 gene mutations all predict increased levels of glutamate in the synaptic 
cleft. Clinical data also suggest the involvement of the glutamatergic system in 
the pathophysiology of depression. (37) Proton magnetic resonance spectroscopy 
(1H-MRS) data suggest alterations to glutamatergic concentrations in several brain 
areas, whereas post-mortem studies indicate alterations in NMDA receptor subunit 
expression in patients with major depressive disorder. The finding that depression 
is highly prevalent in patients with hemiplegic migraine contributes to the 
evidence that the glutamatergic system might be involved in the pathophysiology 
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of depression. It would be interesting to study the role of ion channels encoded by 
CACNA1A, ATP1A2 and SCN1A in large cohorts with comorbid depression and 
common forms of migraine.
9.2.7 Genetic factors involved in chronic migraine
An important drawback of focusing on subgroups of patients, as we did in chapter 
7 with chronic and high-frequent migraine, is that the number of available patients 
decreases. Thus, to increase homogeneity, we had to sacrifice statistical power. 
Although we collaborated in the International Headache Genetics Consortium, 
the patient numbers were relatively small, largely because of the rarity of chronic 
migraine and poor clinical characterization of migraineurs in other cohorts. 
Considering the negative results of the study, our approach may have had 
insufficient statistical power, or we may have selected SNPs irrelevant to migraine 
chronification. If the problem of statistical power will remain problematic, we 
would like to put forward that perhaps other genetic approaches will be more 
fruitful in detecting genes and pathways involved in chronic migraine, such as 
gene expression studies, epigenetic studies or the analysis of rare variants.
9.2.8 Depression in cluster headache
The marked relationship of depression and sleep disturbances in cluster 
headache (chapter 8) adds to the hypothesis that hypothalamic dysfunction 
plays a role, as depression, sleep disorders and cluster headache have all been 
associated with both functional and structural changes in this part of the brain. 
(38-42) Interestingly, depression scores were increased in patients with chronic 
cluster headache, when compared with patients with episodic cluster headache. 
This reminds of the relationship between depression and migraine chronification, 
as described in chapters 2 and 3. However, due to the cross-sectional nature 
of our study, we could not distinguish between cause and consequence. 
Likewise, we could not determine whether depression and cluster headache 
show bidirectional comorbidity. It could still be possible that the pain in cluster 
headache is thus severe, that depression is an almost unavoidable consequence 
– an argument supported by the fact that a stronger association was found for 
chronic cluster headache. The necessary long-term, prospective follow-up design 
for a study to prove bidirectional comorbidity (1, 2), will be challenging because 
of the low prevalence of cluster headache. Longitudinal studies within a cluster 
headache population could shed more light on the process of cluster headache 
chronification, and its relation with depression, cutaneous allodynia and sleep 
disturbances. Further research should also focus on the pathophysiological 
background of the interactions between cluster headache, sleep disturbances, 
chronification of disease, and depression. Comparable to migraine, cutaneous 
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allodynia might provide clues to pathophysiological processes involved in this 
comorbidity. Genetic analyses could either way contribute, with consideration of 
the limitations that rare diseases involve, in particular a lack of statistical power to 
detect genetic variants with a small effect.
9.2.9 The treatment of medication overuse headache
Psychological phenomena play an important role in patients with chronic headache 
or high headache related disability. They are more prone to use unsuitable coping 
mechanisms, score low on pain acceptance and high on catastrophizing scales, 
and experience a low internal pain control. (43-45) Interestingly, in patients with 
migraine, pain control and self-management can be improved by cognitive 
behavioural therapy. (46) It seems likely that all these elements play a role in 
successful withdrawal with support of a headache nurse (chapter 6). Further 
research, specifically focusing on cognitive-behavioural interventions before and 
during withdrawal, might further improve the success rate of withdrawal therapy.
Over the last few years a shift has occurred in the approach of patients with 
medication overuse. Traditionally, it was advised to withdraw patients from their 
overused medication before starting any prophylactic agent. Randomised trials in 
chronic migraine with topiramate and onabotulinum toxin A, however, contributed 
significantly to the debate whether, and when detoxification is necessary in the 
treatment of medication overuse headache. (47-51) In our opinion, it would be 
interesting to study whether Onabotulinum toxin A could be effective for patients 
who do not respond to withdrawal therapy, or whether Onabotulinum toxin A 
could mitigate the process of medication withdrawal.
9.2.10 A critical discussion of the methodology
An important part of the analyses in this thesis was carried out with material from 
two large databases we have compiled over the course of years: the LUMINA 
migraine population (52) and the LUCA cluster headache population. (53) The 
LUMINA database started in 2008 as a web-based method to include migraine 
patients in several research projects, but first and foremost in our genetic data 
collection project. The LUCA database, including cluster headache patients, 
started a few years later, using the same methodology and technical infrastructure 
as LUMINA. During the years, an increasing number of satellite projects was added 
to the LUMINA and LUCA databases, meaning that participants received additional 
requests for questionnaires, biochemical research, Magnetic Resonance Imaging 
and –Spectroscopy studies, migraine attack provocation studies, and even a 
clinical trial on the effect of Onabotulinum Toxin A in the treatment of chronic 
migraine. Collection of a healthy control population started years after the first 
migraine patients were included. Also, data collection via our outpatient clinic was 
introduced into the LUMINA project.
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As described, the primary focus of the LUMINA database had always been 
the collection of DNA samples from migraine patients, in order to be able to 
participate with considerable numbers of samples in the International Headache 
Genetics Consortium. This meant that the database was not optimally equipped 
for epidemiological research questions. We unfortunately had to go back to 
our patients with additional questionnaires a few times, thereby decreasing the 
adherence of our population, and decreasing the numbers of eligible patients. 
Another consideration regarding the LUMINA and LUCA databases is the question 
whether the use of these kinds of database for a range of different clinical questions 
is allowed by the rules of statistics. Conservative voices might argue that only 1 
pre-defined question could be answered using such a database, with a number of 
included patients calculated beforehand using a power calculation. Probably they 
will state that for every new question, a correction for multiple comparison should 
be introduced in the analyses, to reduce the risk of a false positive result to 5% (the 
type-I error). The exact count of the number of tests however, remains a difficult 
issue. Should we count all statistical tests regarding a specific issue, or all tests in 
one chapter of this thesis, or all tests ever performed within the LUMINA database 
during its lifetime? According to the well-known epidemiologist Rothman, ‘the 
policy of not making adjustments for multiple comparisons is preferable because 
it will lead to fewer errors of interpretation when the data under evaluation are 
not random numbers but actual observations on nature’, whereas a basic premise 
of empirical research is that nature follows a regular law, and an expected order, 
that may be studied through observations. (54) We have concluded that, if the 
hypothesis is strictly defined in advance, with one primary outcome measure 
and at most a few secondary outcome measures, and a statistical plan has been 
designed which is followed exactly during the analyses, without extensive post-
hoc sub-group analyses, no correction for multiple testing is needed if it were only 
for the fact that several papers arise from one and the same database. LUMINA 
and LUCA are both progressively growing databases, with new patients entering 
almost on a daily basis. As a consequence, future research questions will be 
answered in a (partially) different population. It is needless to say that the extent 
of both databases allows for more than one research question. Lastly, research 
questions in LUMINA and LUCA are most of the time not fully independent, which 
makes strict correction for multiple testing (i.e. following the Bonferroni correction) 
a too conservative choice.
Although we previously described the LUMINA population as a clinical based 
cohort, we now feel that it is better to describe it as a ‘well-defined, web-based 
migraine population’. In fact, it is a mix of clinical based and population based 
participants, because of the collection via our website. In the LUMINA population 
70% used triptans. Compared to other countries this may seem high but in the 
Netherlands and some Scandinavian countries the use of triptans in population 
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based studies is amongst the highest. Furthermore, 87% was previously diagnosed 
with migraine by a physician, 26% is currently seen by a neurologist, 43% by a 
general practitioner. The remaining 31% is not seen by a neurologist or a general 
practitioner. This proves that the LUMINA population contains the full range of 
migraine patients. 
For the LUCA population, a clinically confirmed diagnosis of cluster headache by 
a physician was available for 94%. For the remaining 6%, no clinically confirmed 
diagnosis was available, for instance because they never consulted a doctor. Still, 
for cluster headache it is almost impossible to collect a population based cohort, 
because of the low prevalence. 
Lastly, we would not use our algorithm for lifetime depression in our daily psychiatric 
practice, whereas we think that the eye of the experienced and evidence-based 
working clinician is the only guarantee for reliable depression diagnoses. In clinical 
practice it is most important to combine symptoms, as presented by the patients, 
with the archetypical presentation of depression as we want to observe in our 
psychiatric examination, and which thereafter might fit into our classification system 
as a ´DSM-5 defined depression’. Clearly, the use of self-report questionnaires 
could never replace this kind of diagnostic finesse. Nevertheless, we would like 
to defend our depression definition as an accurate measurement for purposes of 
scientific research, knowing that extensive psychiatric examination is impracticable 
if the primary purpose of the project is to collect thousands of patients for genetic 
research. 
9.2.11 Clinical implications of our findings
Chapter 2 and chapter 3 show clear involvement of cutaneous allodynia in the 
triad of migraine chronification, depression, and medication overuse. Clinically, 
central sensitization causes refractoriness to acute treatment. (21) Thus, allodynia 
has consequences for disease progression and treatment, and it should lead 
to an increased awareness of comorbidity of migraine and depression, and 
of risk of chronification of migraine. As described in chapter 3, the clinical 
findings from this study correspond with the pathophysiological mechanism of 
CA. The underlying mechanism of migraine and allodynia is activation of the 
trigeminovascular neurons. (55) The activation of the trigeminovascular pathway 
contributes: i) to the headache phase of the migraine attack by sensitization of 
peripheral trigeminovascular neurons innervating the meninges; ii) to the cephalic 
allodynia by sensitization of second-order neurons in the spinal trigeminal nucleus 
(in the medullary dorsal horn) that receive input form the meninges, scalp and 
facial skin; and iii) to the development of extracephalic allodynia by third-order 
neurons in the posterior thalamic nuclei which receive input form meninges, facial 
and body skin. (55) Importantly, once established, sensitization of second order 
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trigeminovascular neurons becomes activity independent, and maintains itself 
in the absence of sensory input later on. (55) The activity-independent form is 
the consequence of neurotransmitter and neuromodulator induced activation 
of multiple intracellular signalling pathways. Activity-independent sensitization 
develops slowly over several hours and lasts for a prolonged period of time. (56) 
This has important clinical implications, as late treatment with triptans during an 
attack is unsuccessful when this independent activity has occurred. (21) Finding 
out which critical thresholds are exceeded before central sensitization occurs will 
potentially lead to new medications preventing sensitization. 
The high prevalence of depression in our HM cohort, described in chapter 4, also 
may have clinical implications. HM patients should be screened for depression, 
and migraine prophylactics such as flunarizine or topiramate which may provoke 
depressive symptoms should perhaps be prescribed with caution in HM patients 
with active depression. (57)
Previous studies suggest that patients with (chronic) headache or high headache 
related disability, are more prone to use unsuitable coping mechanisms (43), score 
low on pain acceptance (44) and high on catastrophizing scales, and experience 
a low internal pain control. (45) In patients with migraine, pain control and self-
management can be improved by behavioural therapy. (46) We hypothesize that 
contact with a headache nurse (chapter 6) influences the above-mentioned factors 
and thus will help patients to endure the withdrawal period. With the support of 
a headache nurse, comprising only one face-to-face contact and a median of 
three contacts by telephone, 75% of patients with medication overuse headache 
succeed to undergo a highly cost-effective outpatient withdrawal therapy, which is 
easily implemented in general neurology practice.
Our data from chapter 8 suggest that current cluster headache attacks are 
associated with increased symptoms of depression, and worse sleep quality. 
Therefore, we may conclude that unsuccessful treatment of cluster headache 
is associated with poor outcomes: depression and sleeping problems. This 
underlines the importance of adequate treatment for cluster headache. Another 
striking and clinically potentially relevant finding of our study was that, in all 
likelihood, depression is considerably underdiagnosed and undertreated in 
cluster headache patients. Early detection of comorbid depression in cluster 
headache may be important to prevent suicide in this unbearably painful primary 
headache disorder.
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Hoewel voorheen al onderzoek is verschenen naar verschillende onderdelen van 
de migrainedriehoek: chronificatie, depressie, en medicatieafhankelijkheid, waren 
er nog altijd ontbrekende stukken van de puzzel. Dit proefschrift onderzocht 
verschillende aspecten van deze driehoeksrelatie, waarbij wij ons richtten op:
· klinische determinanten van depressie in migrainepatiënten (hoofdstuk 
2 en 3),
· de associatie van depressie met migraine aanvalsfrequentie, zowel in 
dwarsdoorsnede onderzoek (hoofdstuk 2) als in longitudinale studieopzet 
(hoofdstuk 3),
· de rol van allodynie van de huid in zowel de comorbiditeit met depressie 
alsook migraine chronificatie (hoofdstuk 2 en 3),
· symptoomdimensies van affectieve stoornissen in migrainepatiënten, 
in vergelijking met personen zonder migraine met en zonder affectieve 
aandoeningen (hoofdstuk 5),
· de comorbiditeit van depressie in hemiplegische migraine, als een 
monogenetisch migraine fenotype (hoofdstuk 4),
· genetische factoren die betrokken zijn bij migraine chronificatie (hoofdstuk 
7),
· de comorbiditeit van depressie in clusterhoofdpijn, als een ernstige 
episodische primaire hoofdpijnvorm anders dan migraine (hoofdstuk 8), 
en
· de behandeling van medicatieafhankelijke hoofdpijn.
De meest opmerkelijke bevindingen worden samengevat in dit hoofdstuk.
Hoofdstuk 1 biedt een algemene introductie in het onderwerp van dit proefschrift. 
Epidemiologie, criteria, pathofysiologie, genetica, en behandeling van zowel 
migraine als depressie worden beschreven, alsook migraine chronificatie en de 
rol van medicatieafhankelijkheid. Voorts voorziet het hoofdstuk in een introductie 
over de comorbiditeit van migraine met depressie, wat we daarover al weten, en 
specifieke overblijvende vragen die in dit proefschrift behandeld zullen worden.
In hoofdstuk 2 wordt de comorbiditeit van migraine met depressie bestudeerd in 
onze LUMINA populatie, inclusief de identificatie van migraine specifieke factoren 
die betrokken zijn bij deze associatie. In een groep met 2533 migrainepatiënten, 
voldeden er 1137 (45%) aan de criteria voor lifetime depressie. Een hoge migraine 
aanvalsfrequentie en de aanwezigheid van huidallodynie bleken migraine 
specifieke factoren geassocieerd met een toegenomen prevalentie van depressie. 
Verder waren slecht slapen, het vrouwelijk geslacht, een hoge BMI, alleenstaand 
zijn, roken, en een lage alcoholconsumptie algemene determinanten van depressie 
in onze populatie. Deze studie identificeerde allodynie, in aanvulling op een hoge 
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aanvalsfrequentie, als een nieuwe migraine specifieke factor geassocieerd met 
depressie. 
Hoofdstuk 3 beschrijft een studie onder 2331 migrainepatiënten uit de 
LUMINA populatie, waarbij we onderzoek deden naar huidallodynie (de 
gewaarwording van pijn als reactie op een niet-pijnlijke prikkel op de normale 
huid), in een longitudinale studieopzet. Allodynie wordt beschouwd als een 
klinische aanduiding voor centrale sensitizatie. We onderzochten of allodynie in 
migrainepatiënten een voorspeller kon zijn voor migraine chronificatie. Allodynie 
bleek, naar verwachting, hoogprevalent in onze migraineurs: 70% gaf aan 
allodynie te hebben tijdens migraineaanvallen. Allodynie bleek geassocieerd 
met de aanwezigheid van depressie (OR 1.52, 95% BI 1.26-1.84), alsook met 
het vrouwelijk geslacht, een lage leeftijd bij aanvang van de migraine, en een 
hoge migraine aanvalsfrequentie. Analyse van de longitudinale data liet zien 
dat allodynie een onafhankelijke voorspeller is voor een toename in het aantal 
migrainedagen gedurende een mediane follow-up duur van 2 jaar.
Als monogenetisch subtype is Hemiplegische Migraine (HM) een meer homogeen 
model om migraine pathofysiologie te bestuderen dan migraine subtypes met 
een complexer genetische achtergrond (zoals migraine met en zonder aura). 
Zodoende presenteren we in hoofdstuk 4 een cross-sectionele studie onder 
89 goed gedefinieerde HM patiënten en 235 gezonde controles. HM patiënten 
vertoonden een verhoogde odds voor lifetime depressie (OR 3.73, 95% BI 2.18-
6.38) in vergelijking met controles. Het gebruik van acute anti-migraine medicatie 
was geassocieerd met lifetime depressie.
In hoofdstuk 5 beschrijven we een studie waarin we voor het eerst een onderscheid 
maken naar symptoomdimensies van het affectieve stoornissen spectrum in een 
grote hoeveelheid migrainepatiënten. Hierbij worden 3174 migrainepatiënten 
uit de LUMINA populatie vergeleken met 561 gezonde controles, 1129 patiënten 
met huidige psychopathologie, en 477 patiënten met psychopathologie in het 
verleden, alle afkomstig van de NESDA populatie. Gebruikmakend van de MASQ-
30 vragenlijst werden depressieve symptomen dimensioneel gemeten, waarbij 
werd gefocust op 3 symptoomdomeinen: het gebrek aan positief affect, somatische 
opwinding, en negatief affect. Migrainepatiënten verschilden significant van 
gezonde controles op alle 3 dimensies. Voor het gebrek aan positief affect en 
de negatief affect dimensie waren migrainepatiënten vergelijkbaar met de groep 
patiënten met psychopathologie in het verleden. Voor de dimensie somatische 
opwinding waren de scores van migrainepatiënten veel meer vergelijkbaar met 
de groep patiënten met huidige psychopathologie.
Hoofdstuk 6 beschrijft een retrospectieve gecontroleerde follow-up studie in 
406 patiënten met medicatieafhankelijke hoofdpijn, met als doel vast te stellen 
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of de ondersteuning van een hoofdpijnverpleegkundige bij de behandeling 
van medicatieafhankelijke hoofdpijn, en om determinanten van respons op 
ontwenningsbehandeling te bestuderen. De percentages voor succesvol afkicken 
waren significant hoger in de groep die door een hoofdpijnverpleegkundige 
werd begeleid dan in de groep zonder begeleiding (73.1% vs. 60.7%, p=0.008), 
wat werd bevestigd in multivariate analyse (OR 1.73, 95 BI 1.11-2.71, p=0.016). 
Ondersteuning door een hoofdpijnverpleegkundige was niet geassocieerd 
met respons (een reductie van 50% of meer in het aantal hoofdpijndagen, na 
succesvol afkicken). De onderliggende primaire hoofdpijndiagnose, vastgesteld 
na afkicken, was significant gecorreleerd met respons (met een sterkere respons 
in de groep met onderliggend migraine, dan in de groep met onderliggend 
spanningshoofdpijn).
Om voor het eerst inzicht te verwerven in de genetische achtergrond van 
chronische migraine, beschrijven we in hoofdstuk 7 een studie waarvan het 
doel was om te zoeken naar bewijs dat genetische factoren betrokken zijn bij 
het chronificatieproces van migraine. Na selectie van 144 single nucleotide 
polymorphisms (SNPs) uit 48 kandidaatgenen, testten we voor een associatie in 
twee stappen: de eerste stage bevatte 262 chronische migrainepatiënten, de 
tweede stage 226 patiënten met hoog-frequente migraine. Acht SNPs waren 
significant geassocieerd met zowel chronische migraine als hoog-frequente 
migraine. Geen van deze SNPs overleefde echter de replicatiefase, waardoor deze 
studie geen significante resultaten opleverde.
We wilden onderzoeken of de associatie van hoofdpijnaanvallen met depressie 
specifiek was voor migraine. Omdat clusterhoofdpijn verscheidene klinische, 
therapeutische en pathofysiologische overeenkomsten vertoont met migraine, 
en studies betreffende de comorbiditeit van clusterhoofdpijn met depressie 
ontbraken, bleef de vraag over of depressie tevens comorbide was met 
clusterhoofdpijn. Hoofdstuk 8 beschrijft dat 44% van de 462 clusterhoofdpijn 
patiënten uit de LUCA populatie voldoet aan de criteria voor lifetime depressie 
(OR 2.77, 95% BI 1.70-4.51). Chronische (n=67) vs. episodische (n=394) patiënten 
hadden een hogere prevalentie van lifetime depressie en meer slaapproblemen. 
Huidige depressie was geassocieerd met huidige aanvallen (laatste aanval minder 
dan 1 maand geleden) (gecorrigeerde p=0.02), maar dit effect verdween na 
correctie voor slaapproblemen.
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